- Table of Contents
- Introduction
- Material and Methods
- First Section: Putative CSF biomarkers of Alzheimer’s disease based on the novel concept of generic protein misfolding and proteotoxicity: the PRAMA cohort
- Second Section: A single domain antibody detects and neutralises toxic Aβ42 oligomers in the Alzheimer’s disease CSF
- Third Section: Design of a dimeric-nanobody specific for Aβ42 oligomers: the Dimeric-DesAb-O
- Discussion
- Conclusion and Future Perspectives
- References
- Index of names
It is available online at https://doi.org/10.36253/979-12-215-0993-9
References
2021 Alzheimer’s disease facts and figures. (2021). Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 17(3), 327–406.
10.1002/alz.12328
2023 Alzheimer’s disease facts and figures. (2023). Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 19(4), 1598–1695.
10.1002/alz.13016
Abelein, A., Chen, G., Kitoka, K., Aleksis, R., Oleskovs, F., Sarr, M., Landreh, M., Pahnke, J., Nordling, K., Kronqvist, N., Jaudzems, K., Rising, A., Johansson, J., & Biverstål, H. (2020). High-yield Production of Amyloid-β Peptide Enabled by a Customized Spider Silk Domain. Scientific Reports, 10(1), 235.
10.1038/s41598-019-57143-x
Ackaert, C., Smiejkowska, N., Xavier, C., Sterckx, Y. G. J., Denies, S., Stijlemans, B., Elkrim, Y., Devoogdt, N., Caveliers, V., Lahoutte, T., Muyldermans, S., Breckpot, K., & Keyaerts, M. (2021). Immunogenicity Risk Profile of Nanobodies. Frontiers in Immunology, 12, 632687.
10.3389/fimmu.2021.632687
M. Ahmed, J. Davis, D. Aucoin, T. Sato, S. Ahuja, S. Aimoto, J. I. Elliott, W. E. Van Nostrand, S. O. Smith. Nature Structural & Molecular Biology, 17(5):561-7
10.1038/nsmb.1799
Alzheimer’s Disease and Dementia. Aducanumab Discontinued as an Alzheimer’s Treatment. (n.d.). Alzheimer’s Disease and Dementia. https://www.alz.org/alzheimers-dementia/treatments/aducanumab
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., Snyder, P. J., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011). The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia, 7(3), 270–279.
10.1016/j.jalz.2011.03.008
Alonso, A. D., Cohen, L. S., Corbo, C., Morozova, V., ElIdrissi, A., Phillips, G., & Kleiman, F. E. (2018). Hyperphosphorylation of Tau Associates with Changes in Its Function Beyond Microtubule Stability. Frontiers in Cellular Neuroscience, 12, 338.
10.3389/fncel.2018.00338
Alzforum. (2023). Remternetug. alzforum.org/therapeutics/remternetug
Alzheimer, A., Stelzmann, R. A., Schnitzlein, H. N., & Murtagh, F. R. (1995). An English translation of Alzheimer’s 1907 paper, ‘Uber eine eigenartige Erkankung der Hirnrinde’. Clinical Anatomy, 8(6), 429–431.
10.1002/ca.980080612
Alzheimer Europe. (2020). Dementia in Europe Yearbook 2019: estimating the prevalence of dementia in Europe. ISBN: 978-99959-995-6-7
Amador-Ortiz, C., Lin, W.-L., Ahmed, Z., Personett, D., Davies, P., Duara, R., Graff-Radford, N. R., Hutton, M. L., & Dickson, D. W. (2007). TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer’s disease. Annals of Neurology, 61(5), 435–445.
10.1002/ana.21154
Amm, I., Sommer, T., & Wolf, D. H. (2014). Protein quality control and elimination of protein waste: The role of the ubiquitin-proteasome system. Biochimica Et Biophysica Acta, 1843(1), 182–196.
10.1016/j.bbamcr.2013.06.031
An, Y., Varma, V. R., Varma, S., Casanova, R., Dammer, E., Pletnikova, O., Chia, C. W., Egan, J. M., Ferrucci, L., Troncoso, J., Levey, A. I., Lah, J., Seyfried, N. T., Legido-Quigley, C., O’Brien, R., & Thambisetty, M. (2018). Evidence for brain glucose dysregulation in Alzheimer’s disease. Alzheimer’s & Dementia, 14(3), 318–329.
10.1016/j.jalz.2017.09.011
Andrews, S. J., Renton, A. E., Fulton-Howard, B., Podlesny-Drabiniok, A., Marcora, E., & Goate, A. M. (2023). The complex genetic architecture of Alzheimer’s disease: Novel insights and future directions. EBioMedicine, 90, 104511.
10.1016/j.ebiom.2023.104511
Angelova, P. R., & Abramov, A. Y. (2018). Role of mitochondrial ROS in the brain: From physiology to neurodegeneration. FEBS Letters, 592(5), 692–702.
10.1002/1873-3468.12964
Antonell, A., Mansilla, A., Rami, L., Lladó, A., Iranzo, A., Olives, J., Balasa, M., Sánchez-Valle, R., & Molinuevo, J. L. (2014). Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer’s disease. Journal of Alzheimer’s Disease: JAD, 42(3), 901–908.
10.3233/JAD-140624
Aprile, F. A., Sormanni, P., Perni, M., Arosio, P., Linse, S., Knowles, T. P. J., Dobson, C. M., & Vendruscolo, M. (2017). Selective targeting of primary and secondary nucleation pathways in Aβ42 aggregation using a rational antibody scanning method. Science Advances, 3(6), e1700488.
10.1126/sciadv.1700488
Aprile, F. A., Sormanni, P., Podpolny, M., Chhangur, S., Needham, L.-M., Ruggeri, F. S., Perni, M., Limbocker, R., Heller, G. T., Sneideris, T., Scheidt, T., Mannini, B., Habchi, J., Lee, S. F., Salinas, P. C., Knowles, T. P. J., Dobson, C. M., & Vendruscolo, M. (2020). Rational design of a conformation-specific antibody for the quantification of Aβ oligomers. Proceedings of the National Academy of Sciences of the United States of America, 117(24), 13509–13518.
10.1073/pnas.1919464117
Arbel-Ornath, M., Hudry, E., Boivin, J. R., Hashimoto, T., Takeda, S., Kuchibhotla, K. V., Hou, S., Lattarulo, C. R., Belcher, A. M., Shakerdge, N., Trujillo, P. B., Muzikansky, A., Betensky, R. A., Hyman, B. T., & Bacskai, B. J. (2017). Soluble oligomeric amyloid-β induces calcium dyshomeostasis that precedes synapse loss in the living mouse brain. Molecular Neurodegeneration, 12(1), 27.
10.1186/s13024-017-0169-9
Argos, P. (1990). An investigation of oligopeptides linking domains in protein tertiary structures and possible candidates for general gene fusion. Journal of Molecular Biology, 211(4), 943–958.
10.1016/0022-2836(90)90085-Z
Ariga, T., Kobayashi, K., Hasegawa, A., Kiso, M., Ishida, H., & Miyatake, T. (2001). Characterization of high-affinity binding between gangliosides and amyloid beta-protein. Archives of Biochemistry and Biophysics, 388(2), 225–230.
10.1006/abbi.2001.2304
Arispe, N., Diaz, J. C., & Simakova, O. (2007). Abeta ion channels. Prospects for treating Alzheimer’s disease with Abeta channel blockers. Biochimica Et Biophysica Acta, 1768(8), 1952–1965.
10.1016/j.bbamem.2007.03.014
Arndt, J. W., Qian, F., Smith, B. A., Quan, C., Kilambi, K. P., Bush, M. W., Walz, T., Pepinsky, R. B., Bussière, T., Hamann, S., Cameron, T. O., & Weinreb, P. H. (2018). Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β. Scientific Reports, 8(1), 6412.
10.1038/s41598-018-24501-0
Ashton, N. J., Pascoal, T. A., Karikari, T. K., Benedet, A. L., Lantero-Rodriguez, J., Brinkmalm, G., Snellman, A., Schöll, M., Troakes, C., Hye, A., Gauthier, S., Vanmechelen, E., Zetterberg, H., Rosa-Neto, P., & Blennow, K. (2021). Plasma p-tau231: A new biomarker for incipient Alzheimer’s disease pathology. Acta Neuropathologica, 141(5), 709–724.
10.1007/s00401-021-02275-6
Bäckman, L., Jones, S., Berger, A.-K., Laukka, E. J., & Small, B. J. (2005). Cognitive impairment in preclinical Alzheimer’s disease: A meta-analysis. Neuropsychology, 19(4), 520–531.
10.1037/0894-4105.19.4.520
Baghallab, I., Reyes-Ruiz, J. M., Abulnaja, K., Huwait, E., & Glabe, C. (2018). Epitomic Characterization of the Specificity of the Anti-Amyloid Aβ Monoclonal Antibodies 6E10 and 4G8. Journal of Alzheimer’s Disease: JAD, 66(3), 1235–1244.
10.3233/JAD-180582
Balchin, D., Hayer-Hartl, M., & Hartl, F. U. (2016). In vivo aspects of protein folding and quality control. Science (New York, N.Y.), 353(6294), aac4354.
10.1126/science.aac4354
Banchelli, M., Cascella, R., D’Andrea, C., Cabaj, L., Osticioli, I., Ciofini, D., Li, M. S., Skupień, K., de Angelis, M., Siano, S., Cecchi, C., Pini, R., La Penna, G., Chiti, F., & Matteini, P. (2020). Nanoscopic insights into the surface conformation of neurotoxic amyloid β oligomers. RSC Advances, 10(37), 21907–21913.
10.1039/d0ra03799k
Barenholz, Y. (2004). Sphingomyelin and cholesterol: From membrane biophysics and rafts to potential medical applications. Sub-Cellular Biochemistry, 37, 167–215.
10.1007/978-1-4757-5806-1_5
Barrera, N. P., Zhou, M., & Robinson, C. V. (2013). The role of lipids in defining membrane protein interactions: Insights from mass spectrometry. Trends in Cell Biology, 23(1), 1–8.
10.1016/j.tcb.2012.08.007
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., Holtzman, D. M., Santacruz, A., Buckles, V., Oliver, A., Moulder, K., Aisen, P. S., Ghetti, B., Klunk, W. E., McDade, E., … Dominantly Inherited Alzheimer Network. (2012). Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. The New England Journal of Medicine, 367(9), 795–804.
10.1056/NEJMoa1202753
Batko, J., Antosz, K., Miśków, W., Pszczołowska, M., Walczak, K., & Leszek, J. (2024). Chaperones-A New Class of Potential Therapeutic Targets in Alzheimer’s Disease. International Journal of Molecular Sciences, 25(6), 3401.
10.3390/ijms25063401
Bélanger, K., Iqbal, U., Tanha, J., MacKenzie, R., Moreno, M., & Stanimirovic, D. (2019). Single-Domain Antibodies as Therapeutic and Imaging Agents for the Treatment of CNS Diseases. Antibodies (Basel, Switzerland), 8(2), 27.
10.3390/antib8020027
Bellomo, G., Toja, A., Paolini Paoletti, F., Ma, Y., Farris, C. M., Gaetani, L., Salvadori, N., Chiasserini, D., Wojdaƚa, A. L., Concha-Marambio, L., & Parnetti, L. (2024). Investigating alpha-synuclein co-pathology in Alzheimer’s disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay. Alzheimer’s & Dementia, 20(4), 2444–2452.
10.1002/alz.13658
Benedet, A. L., Brum, W. S., Hansson, O., Alzheimer’s Disease Neuroimaging Initiative, Karikari, T. K., Zimmer, E. R., Zetterberg, H., Blennow, K., & Ashton, N. J. (2022). The accuracy and robustness of plasma biomarker models for amyloid PET positivity. Alzheimer’s Research & Therapy, 14(1), 26.
10.1186/s13195-021-00942-0
Benilova, I., Karran, E., & De Strooper, B. (2012). The toxic Aβ oligomer and Alzheimer’s disease: An emperor in need of clothes. Nature Neuroscience, 15(3), 349–357.
10.1038/nn.3028
Bento, C. F., Renna, M., Ghislat, G., Puri, C., Ashkenazi, A., Vicinanza, M., Menzies, F. M., & Rubinsztein, D. C. (2016). Mammalian Autophagy: How Does It Work? Annual Review of Biochemistry, 85, 685–713.
10.1146/annurev-biochem-060815-014556
Berridge, M. J. (1998). Neuronal calcium signaling. Neuron, 21(1), 13–26.
10.1016/s0896-6273(00)80510-3
Berridge, M. J., Lipp, P., & Bootman, M. D. (2000). The versatility and universality of calcium signalling. Nature Reviews. Molecular Cell Biology, 1(1), 11–21.
10.1038/35036035
Bhatia, S., Rawal, R., Sharma, P., Singh, T., Singh, M., & Singh, V. (2022). Mitochondrial Dysfunction in Alzheimer’s Disease: Opportunities for Drug Development. Current Neuropharmacology, 20(4), 675–692.
10.2174/1570159X19666210517114016
Bigi, A., Cascella, R., Fani, G., Bernacchioni, C., Cencetti, F., Bruni, P., Chiti, F., Donati, C., & Cecchi, C. (2023a). Sphingosine 1-phosphate attenuates neuronal dysfunction induced by amyloid-β oligomers through endocytic internalization of NMDA receptors. The FEBS Journal, 290(1), 112–133.
10.1111/febs.16579
Bigi, A., Fani, G., Bessi, V., Napolitano, L., Bagnoli, S., Ingannato, A., Neri, L., Cascella, R., Matteini, P., Sorbi, S., Nacmias, B., Cecchi, C., & Chiti, F. (2024). Putative novel CSF biomarkers of Alzheimer’s disease based on the novel concept of generic protein misfolding and proteotoxicity: The PRAMA cohort. Translational Neurodegeneration, 13(1), 14.
10.1186/s40035-024-00405-0
Bigi, A., Loffredo, G., Cascella, R., & Cecchi, C. (2020). Targeting Pathological Amyloid Aggregates with Conformation-Sensitive Antibodies. Current Alzheimer Research, 17(8), 722–734.
10.2174/1567205017666201109093848
Bigi, A., Lombardo, E., Cascella, R., & Cecchi, C. (2023b). The Toxicity of Protein Aggregates: New Insights into the Mechanisms. International Journal of Molecular Sciences, 24(9), 7974.
10.3390/ijms24097974
Bigi, A., Napolitano, L., Vadukul, D. M., Chiti, F., Cecchi, C., Aprile, F. A., & Cascella, R. (2024a). A single-domain antibody detects and neutralises toxic Aβ42 oligomers in the Alzheimer’s disease CSF. Alzheimer’s Research & Therapy, 16(1), 13.
10.1186/s13195-023-01361-z
Biomarkers Definitions Working Group. (2001). Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clinical Pharmacology and Therapeutics, 69(3), 89–95.
10.1067/mcp.2001.113989
Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S. M., Lee, T., Pope, S. H., Riordan, G. S., & Whitlow, M. (1988). Single-chain antigen-binding proteins. Science (New York, N.Y.), 242(4877), 423–426.
10.1126/science.3140379
Bitan, G., Kirkitadze, M. D., Lomakin, A., Vollers, S. S., Benedek, G. B., & Teplow, D. B. (2003). Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proceedings of the National Academy of Sciences of the United States of America, 100(1), 330–335.
10.1073/pnas.222681699
Blennow, K., Wallin, A., Agren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995). Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease? Molecular and Chemical Neuropathology, 26(3), 231–245.
10.1007/BF02815140
Blessed, G., Tomlinson, B. E., & Roth, M. (1968). The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. The British Journal of Psychiatry: The Journal of Mental Science, 114(512), 797–811.
10.1192/bjp.114.512.797
Bode, D. C., Freeley, M., Nield, J., Palma, M., & Viles, J. H. (2019). Amyloid-β oligomers have a profound detergent-like effect on lipid membrane bilayers, imaged by atomic force and electron microscopy. Journal of Biological Chemistry, 294(19), 7566–7572.
10.1074/jbc.AC118.007195
Boess, F., Sakaoka, S., Abi-Saab, D., Scelsi, M., delmar, P., Hofmann, C., Klein, G., Baudler, M., Doody, R., & Kerchner, G. (2021). Graduation study design: Evaluation of once-weekly subcutaneous administration of gantenerumab on brain amyloid load. Alzheimer’s & Dementia, 17, e052060.
10.1002/alz.052060
Bondi, M. W., Edmonds, E. C., & Salmon, D. P. (2017). Alzheimer’s Disease: Past, Present, and Future. Journal of the International Neuropsychological Society: JINS, 23(9–10), 818–831.
10.1017/S135561771700100X
Bondi, M. W., Monsch, A. U., Galasko, D., Butters, N., Salmon, D. P., & Delis, D. C. (1994). Preclinical cognitive markers of dementia of the Alzheimer type. Neuropsychology, 8(3), 374–384.
10.1037/0894-4105.8.3.374
Braak, H., & Braak, E. (1994). Morphological criteria for the recognition of Alzheimer’s disease and the distribution pattern of cortical changes related to this disorder. Neurobiology of Aging, 15(3), 355–356.
10.1016/0197-4580(94)90032-9
Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry, 72, 248–254.
10.1006/abio.1976.9999
Brehme, M., Voisine, C., Rolland, T., Wachi, S., Soper, J. H., Zhu, Y., Orton, K., Villella, A., Garza, D., Vidal, M., Ge, H., & Morimoto, R. I. (2014). A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease. Cell Reports, 9(3), 1135–1150.
10.1016/j.celrep.2014.09.042
Brilhante-da-Silva, N., de Oliveira Sousa, R. M., Arruda, A., Dos Santos, E. L., Marinho, A. C. M., Stabeli, R. G., Fernandes, C. F. C., & Pereira, S. D. S. (2021). Camelid Single-Domain Antibodies for the Development of Potent Diagnosis Platforms. Molecular Diagnosis & Therapy, 25(4), 439–456.
10.1007/s40291-021-00533-7
Brodaty, H., Heffernan, M., Kochan, N. A., Draper, B., Trollor, J. N., Reppermund, S., Slavin, M. J., & Sachdev, P. S. (2013). Mild cognitive impairment in a community sample: The Sydney Memory and Ageing Study. Alzheimer’s & Dementia, 9(3), 310-317.e1.
10.1016/j.jalz.2011.11.010
Brooks, W. H. (2024). Polyamine Dysregulation and Nucleolar Disruption in Alzheimer’s Disease. Journal of Alzheimer’s Disease, 98(3), 837.
10.3233/JAD-231184
Buchhave, P., Minthon, L., Zetterberg, H., Wallin, A. K., Blennow, K., & Hansson, O. (2012). Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Archives of General Psychiatry, 69(1), 98–106.
10.1001/archgenpsychiatry.2011.155
Budd Haeberlein, S., Aisen, P. S., Barkhof, F., Chalkias, S., Chen, T., Cohen, S., Dent, G., Hansson, O., Harrison, K., von Hehn, C., Iwatsubo, T., Mallinckrodt, C., Mummery, C. J., Muralidharan, K. K., Nestorov, I., Nisenbaum, L., Rajagovindan, R., Skordos, L., Tian, Y., … Sandrock, A. (2022). Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease. The Journal of Prevention of Alzheimer’s Disease, 9(2), 197–210.
10.14283/jpad.2022.30
Butterfield, D. A., & Halliwell, B. (2019). Oxidative stress, dysfunctional glucose metabolism, and Alzheimer disease. Nature Reviews. Neuroscience, 20(3), 148.
10.1038/s41583-019-0132-6
Cadonic, C., Sabbir, M. G., & Albensi, B. C. (2016). Mechanisms of Mitochondrial Dysfunction in Alzheimer’s Disease. Molecular Neurobiology, 53(9), 6078–6090.
10.1007/s12035-015-9515-5
Caillé, I., Allinquant, B., Dupont, E., Bouillot, C., Langer, A., Müller, U., & Prochiantz, A. (2004). Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone. Development, 131(9), 2173–2181.
10.1242/dev.01103
Camberg, J., Doyle, S., Johnston, D., & Wickner, S. (2013). Molecular Chaperones. In Brenner’s Encyclopedia of Genetics (pp. 456–460).
10.1016/B978-0-12-374984-0.00221-7
Canevari, L., Clark, J. B., & Bates, T. E. (1999). Beta-Amyloid fragment 25-35 selectively decreases complex IV activity in isolated mitochondria. FEBS Letters, 457(1), 131–134.
10.1016/s0014-5793(99)01028-5
Capitini, C., Conti, S., Perni, M., Guidi, F., Cascella, R., De Poli, A., Penco, A., Relini, A., Cecchi, C., & Chiti, F. (2014). TDP-43 inclusion bodies formed in bacteria are structurally amorphous, non-amyloid and inherently toxic to neuroblastoma cells. PloS One, 9(1), e86720.
10.1371/journal.pone.0086720
Cardoso, F. M., Ibañez, L. I., Van den Hoecke, S., De Baets, S., Smet, A., Roose, K., Schepens, B., Descamps, F. J., Fiers, W., Muyldermans, S., Depicker, A., & Saelens, X. (2014). Single-domain antibodies targeting neuraminidase protect against an H5N1 influenza virus challenge. Journal of Virology, 88(15), 8278–8296.
10.1128/JVI.03178-13
Carmona, S., Hardy, J., & Guerreiro, R. (2018). The genetic landscape of Alzheimer disease. Handbook of Clinical Neurology, 148, 395–408.
10.1016/B978-0-444-64076-5.00026-0
Caroli, A., & Frisoni, G. B. (2010). The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort. Neurobiology of Aging, 31(8), 1263–1274.
10.1016/j.neurobiolaging.2010.04.024
Cascella, R., Bigi, A., Riffert, D. G., Gagliani, M. C., Ermini, E., Moretti, M., Cortese, K., Cecchi, C., & Chiti, F. (2022). A quantitative biology approach correlates neuronal toxicity with the largest inclusions of TDP-43. Science Advances, 8(30), eabm6376.
10.1126/sciadv.abm6376
Cascella, R., & Cecchi, C. (2021). Calcium Dyshomeostasis in Alzheimer’s Disease Pathogenesis. International Journal of Molecular Sciences, 22(9), 4914.
10.3390/ijms22094914
Cascella, R., Chen, S. W., Bigi, A., Camino, J. D., Xu, C. K., Dobson, C. M., Chiti, F., Cremades, N., & Cecchi, C. (2021). The release of toxic oligomers from α-synuclein fibrils induces dysfunction in neuronal cells. Nature Communications, 12(1), 1814.
10.1038/s41467-021-21937-3
Cascella, R., Conti, S., Mannini, B., Li, X., Buxbaum, J. N., Tiribilli, B., Chiti, F., & Cecchi, C. (2013). Transthyretin suppresses the toxicity of oligomers formed by misfolded proteins in vitro. Biochimica Et Biophysica Acta, 1832(12), 2302–2314.
10.1016/j.bbadis.2013.09.011
Cascella, R., Conti, S., Tatini, F., Evangelisti, E., Scartabelli, T., Casamenti, F., Wilson, M. R., Chiti, F., & Cecchi, C. (2013). Extracellular chaperones prevent Aβ42-induced toxicity in rat brains. Biochimica Et Biophysica Acta, 1832(8), 1217–1226.
10.1016/j.bbadis.2013.04.012
Cascella, R., Evangelisti, E., Bigi, A., Becatti, M., Fiorillo, C., Stefani, M., Chiti, F., & Cecchi, C. (2017). Soluble Oligomers Require a Ganglioside to Trigger Neuronal Calcium Overload. Journal of Alzheimer’s Disease: JAD, 60(3), 923–938.
10.3233/JAD-170340
Cecchi, C., Nichino, D., Zampagni, M., Bernacchioni, C., Evangelisti, E., Pensalfini, A., Liguri, G., Gliozzi, A., Stefani, M., & Relini, A. (2009). A protective role for lipid raft cholesterol against amyloid-induced membrane damage in human neuroblastoma cells. Biochimica Et Biophysica Acta, 1788(10), 2204–2216.
10.1016/j.bbamem.2009.07.019
Chasseigneaux, S., & Allinquant, B. (2012). Functions of Aβ, sAPPα and sAPPβ: Similarities and differences. Journal of Neurochemistry, 120 Suppl 1, 99–108.
10.1111/j.1471-4159.2011.07584.x
Chatani, E., Yuzu, K., Ohhashi, Y., & Goto, Y. (2021). Current Understanding of the Structure, Stability and Dynamic Properties of Amyloid Fibrils. International Journal of Molecular Sciences, 22(9), 4349.
10.3390/ijms22094349
Chatziefstathiou, A., Canaslan, S., Kanata, E., Vekrellis, K., Constantinides, V. C., Paraskevas, G. P., Kapaki, E., Schmitz, M., Zerr, I., Xanthopoulos, K., Sklaviadis, T., & Dafou, D. (2024). SIMOA Diagnostics on Alzheimer’s Disease and Frontotemporal Dementia. Biomedicines, 12(6), 1253.
10.3390/biomedicines12061253
Cheignon, C., Tomas, M., Bonnefont-Rousselot, D., Faller, P., Hureau, C., & Collin, F. (2018). Oxidative stress and the amyloid beta peptide in Alzheimer’s disease. Redox Biology, 14, 450–464.
10.1016/j.redox.2017.10.014
Chen, T., O’Gorman, J., Castrillo-Viguera, C., Rajagovindan, R., Curiale, G. G., Tian, Y., Patel, D., von Rosenstiel, P., von Hehn, C., Salloway, S., Hock, C., Nitsch, R. M., Haeberlein, S. B., Sandrock, A., & Singhal, P. (2024). Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab. Alzheimer’s & Dementia, 20(5), 3406–3415.
10.1002/alz.13755
Chen, X., Zaro, J. L., & Shen, W.-C. (2013). Fusion protein linkers: Property, design and functionality. Advanced Drug Delivery Reviews, 65(10), 1357–1369.
10.1016/j.addr.2012.09.039
Chen, Y. R., & Glabe, C. G. (2006). Distinct early folding and aggregation properties of Alzheimer amyloid-beta peptides Abeta40 and Abeta42: Stable trimer or tetramer formation by Abeta42. Journal of Biological Chemistry, 281(34), 24414–24422.
10.1074/jbc.M602363200
Cheng, B., Gong, H., Xiao, H., Petersen, R. B., Zheng, L., & Huang, K. (2013). Inhibiting Toxic Aggregation of Amyloidogenic Proteins: A Therapeutic Strategy for Protein Misfolding Diseases. Biochimica Et Biophysica Acta, 1830(10), 4860–4871.
10.1016/j.bbagen.2013.05.035
Chételat, G., Arbizu, J., Barthel, H., Garibotto, V., Law, I., Morbelli, S., van de Giessen, E., Agosta, F., Barkhof, F., Brooks, D. J., Carrillo, M. C., Dubois, B., Fjell, A. M., Frisoni, G. B., Hansson, O., Herholz, K., Hutton, B. F., Jack, C. R., Lammertsma, A. A., … Drzezga, A. (2020). Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer’s disease and other dementias. The Lancet Neurology, 19(11), 951–962.
10.1016/S1474-4422(20)30314-8
Chiti, F., & Dobson, C. M. (2006). Protein misfolding, functional amyloid, and human disease. Annual Review of Biochemistry, 75, 333–366.
10.1146/annurev.biochem.75.101304.123901
Chiti, F., & Dobson, C. M. (2017). Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade. Annual Review of Biochemistry, 86, 27–68.
10.1146/annurev-biochem-061516-045115
Ciechanover, A., & Brundin, P. (2003). The ubiquitin proteasome system in neurodegenerative diseases: Sometimes the chicken, sometimes the egg. Neuron, 40(2), 427–446.
10.1016/s0896-6273(03)00606-8
Cinquanta, L., Fontana, D. E., & Bizzaro, N. (2017). Chemiluminescent immunoassay technology: What does it change in autoantibody detection? Auto-Immunity Highlights, 8(1), 9.
10.1007/s13317-017-0097-2
Clapham, D. E. (2007). Calcium signaling. Cell, 131(6), 1047–1058.
10.1016/j.cell.2007.11.028
Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L. (2018). The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade. Journal of Alzheimer’s Disease: JAD, 64(s1), S567–S610.
10.3233/JAD-179941
Cohen, S. I. A., Linse, S., Luheshi, L. M., Hellstrand, E., White, D. A., Rajah, L., Otzen, D. E., Vendruscolo, M., Dobson, C. M., & Knowles, T. P. J. (2013). Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism. Proceedings of the National Academy of Sciences of the United States of America, 110(24), 9758–9763.
10.1073/pnas.1218402110
Colom-Cadena, M., Gelpi, E., Charif, S., Belbin, O., Blesa, R., Martí, M. J., Clarimón, J., & Lleó, A. (2013). Confluence of α-synuclein, tau, and β-amyloid pathologies in dementia with Lewy bodies. Journal of Neuropathology and Experimental Neurology, 72(12), 1203–1212.
10.1097/NEN.0000000000000018
Congdon, E. E., & Sigurdsson, E. M. (2018). Tau-targeting therapies for Alzheimer disease. Nature Reviews. Neurology, 14(7), 399–415.
10.1038/s41582-018-0013-z
Corey-Bloom, J. (2002). The ABC of Alzheimer’s disease: Cognitive changes and their management in Alzheimer’s disease and related dementias. International Psychogeriatrics, 14 Suppl 1, 51–75.
10.1017/s1041610203008664
Colvin, M. T., Silvers, R., Ni, Q. Z., Can, T. V., Sergeyev, I., Rosay, M., Donovan, K. J., Michael, B., Wall, J., Linse, S., & Griffin, R. G. (2016). Atomic Resolution Structure of Monomorphic Aβ42 Amyloid Fibrils. Journal of the American Chemical Society, 138(30), 9663–9674.
10.1021/jacs.6b05129
Cummings, J., Osse, A. M. L., Cammann, D., Powell, J., & Chen, J. (2024). Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease. BioDrugs, 38(1), 5–22.
10.1007/s40259-023-00633-2
Dahlgren, K. N., Manelli, A. M., Stine, W. B., Baker, L. K., Krafft, G. A., & LaDu, M. J. (2002). Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. Journal of Biological Chemistry, 277(35), 32046–32053.
10.1074/jbc.M201750200
Danis, C., Dupré, E., Zejneli, O., Caillierez, R., Arrial, A., Bégard, S., Mortelecque, J., Eddarkaoui, S., Loyens, A., Cantrelle, F.-X., Hanoulle, X., Rain, J.-C., Colin, M., Buée, L., & Landrieu, I. (2022). Inhibition of Tau seeding by targeting Tau nucleation core within neurons with a single domain antibody fragment. Molecular Therapy, 30(4), 1484–1499.
10.1016/j.ymthe.2022.01.009
David, M. A., Jones, D. R., & Tayebi, M. (2014). Potential candidate camelid antibodies for the treatment of protein-misfolding diseases. Journal of Neuroimmunology, 272(1-2), 76-85.
10.1016/j.jneuroim.2014.05.001
de la Monte, S. M., & Tong, M. (2014). Brain metabolic dysfunction at the core of Alzheimer's disease. Biochemical Pharmacology, 88(4), 548-559.
10.1016/j.bcp.2013.12.012
De, S., Whiten, D. R., Ruggeri, F. S., Hughes, C., Rodrigues, M., Sideris, D. I., Taylor, C. G., Aprile, F. A., Muyldermans, S., Knowles, T. P. J., Vendruscolo, M., Bryant, C., Blennow, K., Skoog, I., Kern, S., Zetterberg, H., & Klenerman, D. (2019). Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer’s disease progression. Acta Neuropathologica Communications, 7(1), 120.
10.1186/s40478-019-0777-4
De Strooper, B. (2003). Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron, 38(1), 9–12.
10.1016/s0896-6273(03)00205-8
De Strooper, B., & Karran, E. (2016). The Cellular Phase of Alzheimer’s Disease. Cell, 164(4), 603–615.
10.1016/j.cell.2015.12.056
Demattos, R. B., Lu, J., Tang, Y., Racke, M. M., Delong, C. A., Tzaferis, J. A., Hole, J. T., Forster, B. M., McDonnell, P. C., Liu, F., Kinley, R. D., Jordan, W. H., & Hutton, M. L. (2012). A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer’s disease mice. Neuron, 76(5), 908–920.
10.1016/j.neuron.2012.10.029
Demuro, A., Mina, E., Kayed, R., Milton, S. C., Parker, I., & Glabe, C. G. (2005). Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. Journal of Biological Chemistry, 280(17), 17294–17300.
10.1074/jbc.M500997200
Deng, J., Habib, A., Obregon, D. F., Barger, S. W., Giunta, B., Wang, Y.-J., Hou, H., Sawmiller, D., & Tan, J. (2015). Soluble amyloid precursor protein alpha inhibits tau phosphorylation through modulation of GSK3β signaling pathway. Journal of Neurochemistry, 135(3), 630–637.
10.1111/jnc.13351
B. C. Dickerson, & D. A. Wolk. Neurology, 78(2):84-90
10.1212/WNL.0b013e31823efc6c
Dickey, C. A., Koren, J., Zhang, Y.-J., Xu, Y.-F., Jinwal, U. K., Birnbaum, M. J., Monks, B., Sun, M., Cheng, J. Q., Patterson, C., Bailey, R. M., Dunmore, J., Soresh, S., Leon, C., Morgan, D., & Petrucelli, L. (2008). Akt and CHIP coregulate tau degradation through coordinated interactions. Proceedings of the National Academy of Sciences of the United States of America, 105(9), 3622–3627.
10.1073/pnas.0709180105
Ding, Q., Markesbery, W. R., Chen, Q., Li, F., & Keller, J. N. (2005). Ribosome dysfunction is an early event in Alzheimer’s disease. Journal of Neuroscience, 25(40), 9171–9175.
10.1523/JNEUROSCI.3040-05.2005
Drews, A., De, S., Flagmeier, P., Wirthensohn, D. C., Chen, W.-H., Whiten, D. R., Rodrigues, M., Vincke, C., Muyldermans, S., Paterson, R. W., Slattery, C. F., Fox, N. C., Schott, J. M., Zetterberg, H., Dobson, C. M., Gandhi, S., & Klenerman, D. (2017). Inhibiting the Ca2+ Influx Induced by Human CSF. Cell Reports, 21(11), 3310–3316.
10.1016/j.celrep.2017.11.057
Dufour-Rainfray, D., Beaufils, E., Vourc’h, P., Vierron, E., Mereghetti, L., Gendrot, C., Hommet, C., Andres, C. R., Guilloteau, D., & Mondon, K. (2013). Total protein level in cerebrospinal fluid is stable in elderly adults. Journal of the American Geriatrics Society, 61(10), 1819–1821.
10.1111/jgs.12489
Edelman, G. M. (1970). The structure and function of antibodies. Scientific American, 223(2), 34–42.
10.1038/scientificamerican0870-34
Eisenberg, D., & Jucker, M. (2012). The amyloid state of proteins in human diseases. Cell, 148(6), 1188–1203.
10.1016/j.cell.2012.02.022
Eli Lilly and Company. (2023). Lilly’s Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer’s Disease. investor.lilly.com
Engelman, D. M. (2005). Membranes are more mosaic than fluid. Nature, 438(7068), 578–580.
10.1038/nature04394
Englund, H., Sehlin, D., Johansson, A. S., Nilsson, L. N., Gellerfors, P., Paulie, S., Lannfelt, L., & Pettersson, F. E. (2007). Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. Journal of Neurochemistry, 103(1), 334-45.
10.1111/j.1471-4159.2007.04759.x
Esteves, A., Arduíno, D., Silva, D. F., Martins-Branco, D., Oliveira, C., & Cardoso, S. (2009). Mitochondrial Metabolism in Age-Related Neurodegenerative Disorders: Alzheimer's and Parkinson's Revisited.
10.1007/978-0-387-84835-8_7
Evangelisti, E., Cascella, R., Becatti, M., Marrazza, G., Dobson, C. M., Chiti, F., Stefani, M., & Cecchi, C. (2016). Binding affinity of amyloid oligomers to cellular membranes is a generic indicator of cellular dysfunction in protein misfolding diseases. Scientific Reports, 6, 32721.
10.1038/srep32721
Evangelisti, E., Wright, D., Zampagni, M., Cascella, R., Fiorillo, C., Bagnoli, S., Relini, A., Nichino, D., Scartabelli, T., Nacmias, B., Sorbi, S., & Cecchi, C. (2013). Lipid rafts mediate amyloid-induced calcium dyshomeostasis and oxidative stress in Alzheimer's disease. Current Alzheimer Research, 10(2), 143-53.
10.2174/1567205011310020004
Evangelisti, E., Zampagni, M., Cascella, R., Becatti, M., Fiorillo, C., Caselli, A., Bagnoli, S., Nacmias, B., & Cecchi, C. (2014). Plasma membrane injury depends on bilayer lipid composition in Alzheimer's disease. Journal of Alzheimer's Disease, 41(1), 289-300.
10.3233/JAD-131406
Ewers, M., Mattsson, N., Minthon, L., Molinuevo, J. L., Antonell, A., Popp, J., Jessen, F., Herukka, S.-K., Soininen, H., Maetzler, W., Leyhe, T., Bürger, K., Taniguchi, M., Urakami, K., Lista, S., Dubois, B., Blennow, K., & Hampel, H. (2015). CSF biomarkers for the differential diagnosis of Alzheimer’s disease: A large-scale international multicenter study. Alzheimer’s & Dementia, 11(11), 1306–1315.
10.1016/j.jalz.2014.12.006
Fabiani, C., & Antollini, S. S. (2019). Alzheimer’s Disease as a Membrane Disorder: Spatial Cross-Talk Among Beta-Amyloid Peptides, Nicotinic Acetylcholine Receptors and Lipid Rafts. Frontiers in Cellular Neuroscience, 13, 309.
10.3389/fncel.2019.00309
Fagan, A. M., Mintun, M. A., Shah, A. R., Aldea, P., Roe, C. M., Mach, R. H., Marcus, D., Morris, J. C., & Holtzman, D. M. (2009). Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer’s disease. EMBO Molecular Medicine, 1(8–9), 371–380.
10.1002/emmm.200900048
Fani, G., La Torre, C. E., Cascella, R., Cecchi, C., Vendruscolo, M., & Chiti, F. (2022). Misfolded protein oligomers induce an increase of intracellular Ca2+ causing an escalation of reactive oxidative species. Cellular and Molecular Life Sciences, 79(9), 500.
10.1007/s00018-022-04513-w
Fani, G., Mannini, B., Vecchi, G., Cascella, R., Cecchi, C., Dobson, C. M., Vendruscolo, M., & Chiti, F. (2021). Aβ Oligomers Dysregulate Calcium Homeostasis by Mechanosensitive Activation of AMPA and NMDA Receptors. ACS Chemical Neuroscience, 12(4), 766–781.
10.1021/acschemneuro.0c00811
FDA Office of the Commissioner. (2023). FDA Grants Accelerated Approval for Alzheimer’s Disease Treatment. fda.gov
Ferrer, I. (2002). Differential expression of phosphorylated translation initiation factor 2 alpha in Alzheimer’s disease and Creutzfeldt-Jakob’s disease. Neuropathology and Applied Neurobiology, 28(6), 441–451.
10.1046/j.1365-2990.2002.t01-1-00410.x
Ferrer, I., Blanco, R., Carmona, M., Puig, B., Barrachina, M., Gómez, C., & Ambrosio, S. (2001). Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson’s disease and Dementia with Lewy bodies. Journal of Neural Transmission, 108(12), 1383–1396.
10.1007/s007020100015
Finder, V. H., Vodopivec, I., Nitsch, R. M., & Glockshuber, R. (2010). The recombinant amyloid-beta peptide Abeta1-42 aggregates faster and is more neurotoxic than synthetic Abeta1-42. Journal of Molecular Biology, 396(1), 9–18.
10.1016/j.jmb.2009.12.016
Fitzpatrick, A. W. P., Debelouchina, G. T., Bayro, M. J., Clare, D. K., Caporini, M. A., Bajaj, V. S., Jaroniec, C. P., Wang, L., Ladizhansky, V., Müller, S. A., MacPhee, C. E., Waudby, C. A., Mott, H. R., De Simone, A., Knowles, T. P. J., Saibil, H. R., Vendruscolo, M., Orlova, E. V., Griffin, R. G., & Dobson, C. M. (2013). Atomic structure and hierarchical assembly of a cross-β amyloid fibril. Proceedings of the National Academy of Sciences, 110(14), 5468–5473.
10.1073/pnas.1219476110
Fleisher, A. S., Chen, K., Quiroz, Y. T., Jakimovich, L. J., Gomez, M. G., Langois, C. M., Langbaum, J. B., Ayutyanont, N., Roontiva, A., Thiyyagura, P., Lee, W., Mo, H., Lopez, L., Moreno, S., Acosta-Baena, N., Giraldo, M., Garcia, G., Reiman, R. A., Huentelman, M. J., Kosik, K. S., Tariot, P. N., Lopera, F., & Reiman, E. M. (2012). Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Lancet Neurology, 11(12), 1057-65.
10.1016/S1474-4422(12)70227-2
Fletcher, J. (2023). Lilly’s Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer’s Disease.
Förster, S., Grimmer, T., Miederer, I., Henriksen, G., Yousefi, B. H., Graner, P., Wester, H.-J., Förstl, H., Kurz, A., Dickerson, B. C., Bartenstein, P., & Drzezga, A. (2012). Regional expansion of hypometabolism in Alzheimer’s disease follows amyloid deposition with temporal delay. Biological Psychiatry, 71(9), 792–797.
10.1016/j.biopsych.2011.04.023
Friede, R. L., & Samorajski, T. (1970). Axon caliber related to neurofilaments and microtubules in sciatic nerve fibers of rats and mice. The Anatomical Record, 167(4), 379–387.
10.1002/ar.1091670402
Frisoni, G. B., Fox, N. C., Jack, C. R., Scheltens, P., & Thompson, P. M. (2010). The clinical use of structural MRI in Alzheimer disease. Nature Reviews. Neurology, 6(2), 67–77.
10.1038/nrneurol.2009.215
Frost, D., Gorman, P. M., Yip, C. M., & Chakrabartty, A. (2003). Co-incorporation of A beta 40 and A beta 42 to form mixed pre-fibrillar aggregates. European Journal of Biochemistry, 270(4), 654–663.
10.1046/j.1432-1033.2003.03415.x
Fukuchi, K., Accavitti-Loper, M. A., Kim, H.-D., Tahara, K., Cao, Y., Lewis, T. L., Caughey, R. C., Kim, H., & Lalonde, R. (2006a). Amelioration of amyloid load by anti-Abeta single-chain antibody in Alzheimer mouse model. Biochemical and Biophysical Research Communications, 344(1), 79–86.
10.1016/j.bbrc.2006.03.145
Fukuchi, K., Tahara, K., Kim, H.-D., Maxwell, J. A., Lewis, T. L., Accavitti-Loper, M. A., Kim, H., Ponnazhagan, S., & Lalonde, R. (2006b). Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer’s disease. Neurobiology of Disease, 23(3), 502–511.
10.1016/j.nbd.2006.04.012
Fukumoto, H., Tokuda, T., Kasai, T., Ishigami, N., Hidaka, H., Kondo, M., Allsop, D., & Nakagawa, M. (2010). High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB Journal, 24(8), 2716–2726.
10.1096/fj.09-150359
Fukunaga, S., Ueno, H., Yamaguchi, T., Yano, Y., Hoshino, M., & Matsuzaki, K. (2012). GM1 cluster mediates formation of toxic Aβ fibrils by providing hydrophobic environments. Biochemistry, 51(41), 8125–8131.
10.1021/bi300839u
Georganopoulou, D. G., Chang, L., Nam, J.-M., Thaxton, C. S., Mufson, E. J., Klein, W. L., & Mirkin, C. A. (2005). Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer’s disease. Proceedings of the National Academy of Sciences, 102(7), 2273–2276.
10.1073/pnas.0409336102
Giacomucci, G., Mazzeo, S., Bagnoli, S., Ingannato, A., Leccese, D., Berti, V., Padiglioni, S., Galdo, G., Ferrari, C., Sorbi, S., Bessi, V., & Nacmias, B. (2022). Plasma neurofilament light chain as a biomarker of Alzheimer’s disease in Subjective Cognitive Decline and Mild Cognitive Impairment. Journal of Neurology, 269(8), 4270–4280.
10.1007/s00415-022-11055-5
Gibbs, E., Silverman, J. M., Zhao, B., Peng, X., Wang, J., Wellington, C. L., Mackenzie, I. R., Plotkin, S. S., Kaplan, J. M., & Cashman, N. R. (2019). A Rationally Designed Humanized Antibody Selective for Amyloid Beta Oligomers in Alzheimer’s Disease. Scientific Reports, 9(1), 9870.
10.1038/s41598-019-46306-5
Gill, S. C., & von Hippel, P. H. (1989). Calculation of protein extinction coefficients from amino acid sequence data. Analytical Biochemistry, 182(2), 319–326.
10.1016/0003-2697(89)90602-7
Ginsberg, S. D., Galvin, J. E., Chiu, T. S., Lee, V. M., Masliah, E., & Trojanowski, J. Q. (1998). RNA sequestration to pathological lesions of neurodegenerative diseases. Acta Neuropathologica, 96(5), 487-94.
10.1007/s004010050923
Gisslén, M., Price, R. W., Andreasson, U., Norgren, N., Nilsson, S., Hagberg, L., Fuchs, D., Spudich, S., Blennow, K., & Zetterberg, H. (2016). Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study. EBioMedicine, 3, 135–140.
10.1016/j.ebiom.2015.11.036
Glenner, G. G., & Wong, C. W. (1984). Alzheimer’s disease and Down’s syndrome: Sharing of a unique cerebrovascular amyloid fibril protein. Biochemical and Biophysical Research Communications, 122(3), 1131–1135.
10.1016/0006-291x(84)91209-9
Goedert, M., Masuda-Suzukake, M., & Falcon, B. (2017). Like prions: the propagation of aggregated tau and α-synuclein in neurodegeneration. Brain, 140(2), 266-278.
10.1093/brain/aww230
Golde, T. E., Eckman, C. B., & Younkin, S. G. (2000). Biochemical detection of Abeta isoforms: Implications for pathogenesis, diagnosis, and treatment of Alzheimer’s disease. Biochimica Et Biophysica Acta, 1502(1), 172–187.
10.1016/s0925-4439(00)00043-0
Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L. (2003). Alzheimer’s disease-affected brain: Presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proceedings of the National Academy of Sciences, 100(18), 10417–10422.
10.1073/pnas.1834302100
Gorantla, N. V., & Chinnathambi, S. (2018). Tau Protein Squired by Molecular Chaperones During Alzheimer’s Disease. Journal of Molecular Neuroscience, 66(3), 356–368.
10.1007/s12031-018-1174-3
N. J. Greenfield. Nature Protocols, 1, 2733–2741
10.1038/nprot.2006.202
Greenough, M. A., Camakaris, J., & Bush, A. I. (2013). Metal dyshomeostasis and oxidative stress in Alzheimer’s disease. Neurochemistry International, 62(5), 540–555.
10.1016/j.neuint.2012.08.014
Guerreiro, R. J., Gustafson, D. R., & Hardy, J. (2012). The genetic architecture of Alzheimer’s disease: Beyond APP, PSENs and APOE. Neurobiology of Aging, 33(3), 437–456.
10.1016/j.neurobiolaging.2010.03.025
Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y. (2020). Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease. Molecular Neurodegeneration, 15(1), 40.
10.1186/s13024-020-00391-7
Habiba, U., Descallar, J., Kreilaus, F., Adhikari, U. K., Kumar, S., Morley, J. W., Bui, B. V., Koronyo-Hamaoui, M., & Tayebi, M. (2021). Detection of retinal and blood Aβ oligomers with nanobodies. Alzheimer’s & Dementia (Amsterdam, Netherlands), 13(1), e12193.
10.1002/dad2.12193
Halliwell, B., & Gutteridge, J. M. C. (2015). Free Radicals in Biology and Medicine. Oxford University Press.
10.1093/acprof:oso/9780198717478.001.0001
Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hamers, C., Songa, E. B., Bendahman, N., & Hamers, R. (1993). Naturally occurring antibodies devoid of light chains. Nature, 363(6428), 446–448.
10.1038/363446a0
Hampel, H., Cummings, J., Blennow, K., Gao, P., Jack, C. R., & Vergallo, A. (2021a). Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nature Reviews. Neurology, 17(9), 580–589.
10.1038/s41582-021-00520-w
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., Masters, C. L., Cho, M., Lannfelt, L., Cummings, J. L., & Vergallo, A. (2021b). The Amyloid-β Pathway in Alzheimer’s Disease. Molecular Psychiatry, 26(10), 5481–5503.
10.1038/s41380-021-01249-0
Hansen, D. V., Hanson, J. E., & Sheng, M. (2018). Microglia in Alzheimer’s disease. Journal of Cell Biology, 217(2), 459–472.
10.1083/jcb.201709069
Hansson, O., Janelidze, S., Hall, S., Magdalinou, N., Lees, A. J., Andreasson, U., Norgren, N., Linder, J., Forsgren, L., Constantinescu, R., Zetterberg, H., & Blennow, K. (2017). Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder. Neurology, 88(10), 930–937.
10.1212/WNL.0000000000003680
Hansson, O., Lehmann, S., Otto, M., Zetterberg, H., & Lewczuk, P. (2019). Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease. Alzheimer’s Research & Therapy, 11(1), 34.
10.1186/s13195-019-0485-0
Hardy, J., & Allsop, D. (1991). Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends in Pharmacological Sciences, 12(10), 383–388.
10.1016/0165-6147(91)90609-v
Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science, 297(5580), 353–356.
10.1126/science.1072994
Hashimoto, M., Rockenstein, E., Crews, L., & Masliah, E. (2003). Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer’s and Parkinson’s diseases. Neuromolecular Medicine, 4(1–2), 21–36.
10.1385/NMM:4:1-2:21
Hebda, J. A., & Miranker, A. D. (2009). The Interplay of Catalysis and Toxicity by Amyloid Intermediates on Lipid Bilayers: Insights from Type II Diabetes. Annual Review of Biophysics, 38, 125–152.
10.1146/annurev.biophys.050708.133641
Hefti, F., Goure, W. F., Jerecic, J., Iverson, K. S., Walicke, P. A., & Krafft, G. A. (2013). The case for soluble Aβ oligomers as a drug target in Alzheimer’s disease. Trends in Pharmacological Sciences, 34(5), 261–266.
10.1016/j.tips.2013.03.002
Heneka, M. T., Carson, M. J., El Khoury, J., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., Herrup, K., Frautschy, S. A., Finsen, B., Brown, G. C., Verkhratsky, A., Yamanaka, K., Koistinaho, J., Latz, E., Halle, A., … Kummer, M. P. (2015). Neuroinflammation in Alzheimer’s disease. The Lancet Neurology, 14(4), 388–405.
10.1016/S1474-4422(15)70016-5
Hepp, D. H., Vergoossen, D. L. E., Huisman, E., Lemstra, A. W., Berendse, H. W., Rozemuller, A. J., Foncke, E. M. J., & van de Berg, W. D. J. (2016). Distribution and Load of Amyloid-β Pathology in Parkinson Disease and Dementia with Lewy Bodies. Journal of Neuropathology and Experimental Neurology, 75(10), 936–945.
10.1093/jnen/nlw070
Hernández-Ortega, K., Garcia-Esparcia, P., Gil, L., Lucas, J. J., & Ferrer, I. (2016). Altered Machinery of Protein Synthesis in Alzheimer’s: From the Nucleolus to the Ribosome. Brain Pathology, 26(5), 593–605.
10.1111/bpa.12335
Herring, W. L., Gould, I. G., Fillit, H., Lindgren, P., Forrestal, F., Thompson, R., & Pemberton-Ross, P. (2021). Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer’s Disease. Neurology and Therapy, 10(2), 919–940.
10.1007/s40120-021-00273-0
Hershko, A., & Ciechanover, A. (1998). The ubiquitin system. Annual Review of Biochemistry, 67, 425–479.
10.1146/annurev.biochem.67.1.425
Herskovits, A. Z., Locascio, J. J., Peskind, E. R., Li, G., & Hyman, B. T. (2013). A Luminex assay detects amyloid β oligomers in Alzheimer’s disease cerebrospinal fluid. PloS One, 8(7), e67898.
10.1371/journal.pone.0067898
Heyman, A., Peterson, B., Fillenbaum, G., & Pieper, C. (1996). The consortium to establish a registry for Alzheimer’s disease (CERAD). Part XIV: Demographic and clinical predictors of survival in patients with Alzheimer’s disease. Neurology, 46(3), 656–660.
10.1212/wnl.46.3.656
Hillen, H., Barghorn, S., Striebinger, A., Labkovsky, B., Müller, R., Nimmrich, V., Nolte, M. W., Perez-Cruz, C., van der Auwera, I., van Leuven, F., van Gaalen, M., Bespalov, A. Y., Schoemaker, H., Sullivan, J. P., & Ebert, U. (2010). Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies. Journal of Neuroscience, 30(31), 10369–10379.
10.1523/JNEUROSCI.5721-09.2010
Hipp, M. S., Park, S.-H., & Hartl, F. U. (2014). Proteostasis impairment in protein-misfolding and -aggregation diseases. Trends in Cell Biology, 24(9), 506–514.
10.1016/j.tcb.2014.05.003
Hodges, J. R., Graham, N., & Patterson, K. (1995). Charting the progression in semantic dementia: Implications for the organisation of semantic memory. Memory, 3(3–4), 463–495.
10.1080/09658219508253161
Hof, P. R., Vogt, B. A., Bouras, C., & Morrison, J. H. (1997). Atypical form of Alzheimer’s disease with prominent posterior cortical atrophy: A review of lesion distribution and circuit disconnection in cortical visual pathways. Vision Research, 37(24), 3609–3625.
10.1016/S0042-6989(96)00240-4
Hölttä, M., Hansson, O., Andreasson, U., Hertze, J., Minthon, L., Nägga, K., Andreasen, N., Zetterberg, H., & Blennow, K. (2013). Evaluating amyloid-β oligomers in cerebrospinal fluid as a biomarker for Alzheimer’s disease. PloS One, 8(6), e66381.
10.1371/journal.pone.0066381
Hong, S., Ostaszewski, B. L., Yang, T., O’Malley, T. T., Jin, M., Yanagisawa, K., Li, S., Bartels, T., & Selkoe, D. J. (2014). Soluble Aβ oligomers are rapidly sequestered from brain ISF in vivo and bind GM1 ganglioside on cellular membranes. Neuron, 82(2), 308–319.
10.1016/j.neuron.2014.02.027
Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., et al. (2016). Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science, 352(6286), 712–716.
10.1126/science.aad8373
Huang, W.-J., Zhang, X., & Chen, W.-W. (2016). Role of oxidative stress in Alzheimer’s disease. Biomedical Reports, 4(5), 519–522.
10.3892/br.2016.630
Huang, Y. R., & Liu, R.-T. (2020). The Toxicity and Polymorphism of β-Amyloid Oligomers. International Journal of Molecular Sciences, 21(12), 4477.
10.3390/ijms21124477
Hubin, E., van Nuland, N. a. J., Broersen, K., & Pauwels, K. (2014). Transient dynamics of Aβ contribute to toxicity in Alzheimer’s disease. Cellular and Molecular Life Sciences, 71(18), 3507–3521.
10.1007/s00018-014-1634-z
Hultberg, A., Temperton, N. J., Rosseels, V., Koenders, M., Gonzalez-Pajuelo, M., Schepens, B., Ibañez, L. I., Vanlandschoot, P., Schillemans, J., Saunders, M., Weiss, R. A., Saelens, X., Melero, J. A., Verrips, C. T., Van Gucht, S., & de Haard, H. J. (2011). Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules. PloS One, 6(4), e17665.
10.1371/journal.pone.0017665
Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M. S., Novotný, J., Margolies, M. N., Ridge, R. J., Bruccoleri, R. E., Haber, E., & Crea, R. (1988). Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proceedings of the National Academy of Sciences, 85(16), 5879–5883.
10.1073/pnas.85.16.5879
Hyman, B. T., Van Hoesen, G. W., Damasio, A. R., & Barnes, C. L. (1984). Alzheimer’s disease: Cell-specific pathology isolates the hippocampal formation. Science, 225(4667), 1168–1170.
10.1126/science.6474172
Iadecola, C. (2017). The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease. Neuron, 96(1), 17-42.
10.1016/j.neuron.2017.07.030
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., Liu, E., Molinuevo, J. L., Montine, T., Phelps, C., Rankin, K. P., Rowe, C. C., Scheltens, P., Siemers, E., Snyder, H. M., … Contributors. (2018). NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia, 14(4), 535–562.
10.1016/j.jalz.2018.02.018
Jack, C. R., Dickson, D. W., Parisi, J. E., Xu, Y. C., Cha, R. H., O’Brien, P. C., Edland, S. D., Smith, G. E., Boeve, B. F., Tangalos, E. G., Kokmen, E., & Petersen, R. C. (2002). Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology, 58(5), 750–757.
10.1212/wnl.58.5.750
Jack, C. R., & Holtzman, D. M. (2013). Biomarker modeling of Alzheimer’s disease. Neuron, 80(6), 1347–1358.
10.1016/j.neuron.2013.12.003
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., Lesnick, T. G., Pankratz, V. S., Donohue, M. C., & Trojanowski, J. Q. (2013). Tracking pathophysiological processes in Alzheimer’s disease: An updated hypothetical model of dynamic biomarkers. The Lancet Neurology, 12(2), 207–216.
10.1016/S1474-4422(12)70291-0
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010a). Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. The Lancet Neurology, 9(1), 119–128.
10.1016/S1474-4422(09)70299-6
Jack, C. R., Lowe, V. J., Senjem, M. L., Weigand, S. D., Kemp, B. J., Shiung, M. M., Knopman, D. S., Boeve, B. F., Klunk, W. E., Mathis, C. A., & Petersen, R. C. (2008). 11C PiB and structural MRI provide complementary information in imaging of Alzheimer’s disease and amnestic mild cognitive impairment. Brain, 131(Pt 3), 665–680.
10.1093/brain/awm336
Jack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., Weiner, M., & Petersen, R. C. (2009). Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: Implications for sequence of pathological events in Alzheimer’s disease. Brain, 132(Pt 5), 1355–1365.
10.1093/brain/awp062
Jack, C. R., Vemuri, P., Wiste, H. J., Weigand, S. D., Lesnick, T. G., Lowe, V., Kantarci, K., Bernstein, M. A., Senjem, M. L., Gunter, J. L., Boeve, B. F., Trojanowski, J. Q., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Knopman, D. S. (2012). Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Archives of Neurology, 69(7), 856–867.
10.1001/archneurol.2011.3405
Jack, C. R., Wiste, H. J., Vemuri, P., Weigand, S. D., Senjem, M. L., Zeng, G., Bernstein, M. A., Gunter, J. L., Pankratz, V. S., Aisen, P. S., Weiner, M. W., Petersen, R. C., Shaw, L. M., Trojanowski, J. Q., & Knopman, D. S. (2010b). Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease. Brain, 133(11), 3336–3348.
10.1093/brain/awq277
Jackson, R. J., Hellen, C. U. T., & Pestova, T. V. (2010). The mechanism of eukaryotic translation initiation and principles of its regulation. Nature Reviews. Molecular Cell Biology, 11(2), 113–127.
10.1038/nrm2838
Jagust, W. J. (2010). Amyloid imaging: Coming to a PET scanner near you. Annals of Neurology, 68(3), 277–278.
10.1002/ana.22144
Jakob-Roetne, R., & Jacobsen, H. (2009). Alzheimer’s disease: From pathology to therapeutic approaches. Angewandte Chemie (International Ed. in English), 48(17), 3030–3059.
10.1002/anie.200802808
Janelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., Blennow, K., Reiman, E. M., Stomrud, E., Dage, J. L., & Hansson, O. (2020). Plasma P-tau181 in Alzheimer’s disease: Relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nature Medicine, 26(3), 379–386.
10.1038/s41591-020-0755-1
Janelidze, S., Stomrud, E., Palmqvist, S., Zetterberg, H., van Westen, D., Jeromin, A., Song, L., Hanlon, D., Tan Hehir, C. A., Baker, D., Blennow, K., & Hansson, O. (2016). Plasma β-amyloid in Alzheimer’s disease and vascular disease. Scientific Reports, 6, 26801.
10.1038/srep26801
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Amyloid Biomarker Study Group, Aalten, P., Aarsland, D., Alcolea, D., Alexander, M., Almdahl, I. S., Arnold, S. E., Baldeiras, I., Barthel, H., van Berckel, B. N. M., Bibeau, K., Blennow, K., … Zetterberg, H. (2015). Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. JAMA, 313(19), 1924–1938.
10.1001/jama.2015.4668
Jarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993). The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer’s disease. Biochemistry, 32(18), 4693–4697.
10.1021/bi00069a001
Jekel, K., Damian, M., Wattmo, C., Hausner, L., Bullock, R., Connelly, P. J., Dubois, B., Eriksdotter, M., Ewers, M., Graessel, E., Kramberger, M. G., Law, E., Mecocci, P., Molinuevo, J. L., Nygård, L., Olde-Rikkert, M. G., Orgogozo, J.-M., Pasquier, F., Peres, K., … Frölich, L. (2015). Mild cognitive impairment and deficits in instrumental activities of daily living: A systematic review. Alzheimer’s Research & Therapy, 7(1), 17.
10.1186/s13195-015-0099-0
Ji, S. R., Wu, Y., & Sui, S. (2002). Cholesterol is an important factor affecting the membrane insertion of beta-amyloid peptide (A beta 1-40), which may potentially inhibit the fibril formation. Journal of Biological Chemistry, 277(8), 6273–6279.
10.1074/jbc.M104146200
Jinwal, U. K., Trotter, J. H., Abisambra, J. F., Koren, J., Lawson, L. Y., Vestal, G. D., O’Leary, J. C., Johnson, A. G., Jin, Y., Jones, J. R., Li, Q., Weeber, E. J., & Dickey, C. A. (2011). The Hsp90 kinase co-chaperone Cdc37 regulates tau stability and phosphorylation dynamics. Journal of Biological Chemistry, 286(19), 16976–16983.
10.1074/jbc.M110.182493
Johnson, J. K., Head, E., Kim, R., Starr, A., & Cotman, C. W. (1999). Clinical and pathological evidence for a frontal variant of Alzheimer disease. Archives of Neurology, 56(10), 1233–1239.
10.1001/archneur.56.10.1233
Kagan, B. L., Azimov, R., & Azimova, R. (2004). Amyloid peptide channels. Journal of Membrane Biology, 202(1), 1–10.
10.1007/s00232-004-0709-4
Kakio, A., Nishimoto, S. I., Yanagisawa, K., Kozutsumi, Y., & Matsuzaki, K. (2001). Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid. Journal of Biological Chemistry, 276(27), 24985–24990.
10.1074/jbc.M100252200
Kakio, A., Nishimoto, S., Yanagisawa, K., Kozutsumi, Y., & Matsuzaki, K. (2002). Interactions of amyloid beta-protein with various gangliosides in raft-like membranes: Importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. Biochemistry, 41(23), 7385–7390.
10.1021/bi0255874
Kamat, P. K., Kalani, A., Rai, S., Swarnkar, S., Tota, S., Nath, C., & Tyagi, N. (2016). Mechanism of Oxidative Stress and Synapse Dysfunction in the Pathogenesis of Alzheimer’s Disease: Understanding the Therapeutics Strategies. Molecular Neurobiology, 53(1), 648–661.
10.1007/s12035-014-9053-6
Kaneko, M., Koike, H., Saito, R., Kitamura, Y., Okuma, Y., & Nomura, Y. (2010). Loss of HRD1-mediated protein degradation causes amyloid precursor protein accumulation and amyloid-beta generation. Journal of Neuroscience, 30(11), 3924–3932.
10.1523/JNEUROSCI.2422-09.2010
Kaneko, M., Saito, R., Okuma, Y., & Nomura, Y. (2012). Possible involvement of ubiquitin ligase HRD1 insolubilization in amyloid β generation. Biological & Pharmaceutical Bulletin, 35(2), 269–272.
10.1248/bpb.35.269
Kapasi, A., DeCarli, C., & Schneider, J. A. (2017). Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathologica, 134, 171–186.
10.1007/s00401-017-1717-7
Karch, C. M., Cruchaga, C., & Goate, A. M. (2014). Alzheimer’s disease genetics: From the bench to the clinic. Neuron, 83(1), 11–26.
10.1016/j.neuron.2014.05.041
Karikari, T. K., Pascoal, T. A., Ashton, N. J., Janelidze, S., Benedet, A. L., Rodriguez, J. L., Chamoun, M., Savard, M., Kang, M. S., Therriault, J., Schöll, M., Massarweh, G., Soucy, J.-P., Höglund, K., Brinkmalm, G., Mattsson, N., Palmqvist, S., Gauthier, S., Stomrud, E., … Blennow, K. (2020). Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: A diagnostic performance and prediction modelling study using data from four prospective cohorts. The Lancet Neurology, 19(5), 422–433.
10.1016/S1474-4422(20)30071-5
Karran, E., & De Strooper, B. (2022). The amyloid hypothesis in Alzheimer disease: New insights from new therapeutics. Nature Reviews. Drug Discovery, 21(4), 306–318.
10.1038/s41573-022-00391-w
Kasturirangan, S., Li, L., Emadi, S., Boddapati, S., Schulz, P., & Sierks, M. R. (2012). Nanobody specific for oligomeric β-amyloid stabilizes nontoxic form. Neurobiology of Aging, 33(7), 1320–1328.
10.1016/j.neurobiolaging.2010.09.020
Kayed, R., Head, E., Sarsoza, F., Saing, T., Cotman, C. W., Necula, M., Margol, L., Wu, J., Breydo, L., Thompson, J. L., Rasool, S., Gurlo, T., Butler, P., & Glabe, C. G. (2007). Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Molecular Neurodegeneration, 2, 18.
10.1186/1750-1326-2-18
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003). Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science, 300(5618), 486–489.
10.1126/science.1079469
Kayed, R., Sokolov, Y., Edmonds, B., McIntire, T. M., Milton, S. C., Hall, J. E., & Glabe, C. G. (2004). Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. Journal of Biological Chemistry, 279(45), 46363–46366.
10.1074/jbc.C400260200
Kaushik, S., & Cuervo, A. M. (2015). Proteostasis and aging. Nature Medicine, 21(12), 1406-15.
10.1038/nm.4001
Keck, S., Nitsch, R., Grune, T., & Ullrich, O. (2003). Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer’s disease. Journal of Neurochemistry, 85(1), 115–122.
10.1046/j.1471-4159.2003.01642.x
Khachaturian, Z. S. (1989). The role of calcium regulation in brain aging: Reexamination of a hypothesis. Aging (Milan), 1(1), 17–34.
10.1007/BF03323872
Kim, S., Sharma, C., Jung, U. J., & Kim, S. R. (2023). Pathophysiological Role of Microglial Activation Induced by Blood-Borne Proteins in Alzheimer’s Disease. Biomedicines, 11(5), 1383.
10.3390/biomedicines11051383
Kim, S. I., Yi, J. S., & Ko, Y. G. (2006). Amyloid beta oligomerization is induced by brain lipid rafts. Journal of Cellular Biochemistry, 99(3), 878–889.
10.1002/jcb.20978
Kim, Y. E., Hipp, M. S., Bracher, A., Hayer-Hartl, M., & Hartl, F. U. (2013). Molecular chaperone functions in protein folding and proteostasis. Annual Review of Biochemistry, 82, 323–355.
10.1146/annurev-biochem-060208-092442
Kim, K. S., Wen, G. Y., Bancher, C., Chen, C. M. J., Sapienza, V., Hong, H., & Wisniewski, H. M. (1990). Detection and quantification of amyloid β-peptide with two monoclonal antibodies. Neuroscience Research Communications, 7, 113–122.
Kinger, S., Jagtap, Y. A., Kumar, P., Choudhary, A., Prasad, A., Prajapati, V. K., Kumar, A., Mehta, G., & Mishra, A. (2024). Proteostasis in neurodegenerative diseases. Advances in Clinical Chemistry, 121, 270–333.
10.1016/bs.acc.2024.04.002
Kish, S. J. (1997). Brain energy metabolizing enzymes in Alzheimer’s disease: Alpha-ketoglutarate dehydrogenase complex and cytochrome oxidase. Annals of the New York Academy of Sciences, 826, 218–228.
10.1111/j.1749-6632.1997.tb48473.x
Kleiger, G., & Mayor, T. (2014). Perilous journey: A tour of the ubiquitin-proteasome system. Trends in Cell Biology, 24(6), 352–359.
10.1016/j.tcb.2013.12.003
Klement, M., Liu, C., Loo, B. L. W., Choo, A. B.-H., Ow, D. S.-W., & Lee, D.-Y. (2015). Effect of linker flexibility and length on the functionality of a cytotoxic engineered antibody fragment. Journal of Biotechnology, 199, 90–97.
10.1016/j.jbiotec.2015.02.008
Klyubin, I., Betts, V., Welzel, A. T., Blennow, K., Zetterberg, H., Wallin, A., Lemere, C. A., Cullen, W. K., Peng, Y., Wisniewski, T., Selkoe, D. J., Anwyl, R., Walsh, D. M., & Rowan, M. J. (2008). Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: Prevention by systemic passive immunization. Journal of Neuroscience, 28(16), 4231–4237.
10.1523/JNEUROSCI.5161-07.2008
Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021). Alzheimer disease. Nature Reviews. Disease Primers, 7(1), 33.
10.1038/s41572-021-00269-y
Kollmer, M., Close, W., Funk, L., Rasmussen, J., Bsoul, A., Schierhorn, A., Schmidt, M., Sigurdson, C. J., Jucker, M., & Fändrich, M. (2019). Cryo-EM structure and polymorphism of Aβ amyloid fibrils purified from Alzheimer’s brain tissue. Nature Communications, 10(1), 4760.
10.1038/s41467-019-12683-8
Kosik, K. S., Joachim, C. L., & Selkoe, D. J. (1986). Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proceedings of the National Academy of Sciences, 83(11), 4044–4048.
10.1073/pnas.83.11.4044
Kravats, A. N., Wickner, S., & Camberg, J. L. (2022). Molecular Chaperones. Reference Module in Life Sciences.
10.1016/B978-0-12-809633-8.21045-8
Kremer, J. J., Pallitto, M. M., Sklansky, D. J., & Murphy, R. M. (2000). Correlation of beta-amyloid aggregate size and hydrophobicity with decreased bilayer fluidity of model membranes. Biochemistry, 39(33), 10309–10318.
10.1021/bi0001980
Kulichikhin, K. Y., Fedotov, S. A., Rubel, M. S., Zalutskaya, N. M., Zobnina, A. E., Malikova, O. A., Neznanov, N. G., Chernoff, Y. O., & Rubel, A. A. (2021). Development of molecular tools for diagnosis of Alzheimer’s disease that are based on detection of amyloidogenic proteins. Prion, 15(1), 56–69.
10.1080/19336896.2021.1917289
Labbadia, J., & Morimoto, R. I. (2015). The biology of proteostasis in aging and disease. Annual Review of Biochemistry, 84, 435–464.
10.1146/annurev-biochem-060614-033955
Ladiwala, A. R. A., Litt, J., Kane, R. S., Aucoin, D. S., Smith, S. O., Ranjan, S., Davis, J., Van Nostrand, W. E., & Tessier, P. M. (2012). Conformational differences between two amyloid β oligomers of similar size and dissimilar toxicity. Journal of Biological Chemistry, 287(29), 24765–24773.
10.1074/jbc.M111.329763
Lafaye, P., Achour, I., England, P., Duyckaerts, C., & Rougeon, F. (2009). Single-domain antibodies recognize selectively small oligomeric forms of amyloid beta, prevent Abeta-induced neurotoxicity and inhibit fibril formation. Molecular Immunology, 46(4), 695–704.
10.1016/j.molimm.2008.09.008
LaFerla, F. M., Green, K. N., & Oddo, S. (2007). Intracellular amyloid-beta in Alzheimer’s disease. Nature Reviews. Neuroscience, 8(7), 499–509.
10.1038/nrn2168
Lafleche, G., & Albert, M. S. (1995). Executive function deficits in mild Alzheimer’s disease. Neuropsychology, 9(3), 313–320.
10.1037/0894-4105.9.3.313
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., Wals, P., Zhang, C., Finch, C. E., Krafft, G. A., & Klein, W. L. (1998). Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proceedings of the National Academy of Sciences, 95(11), 6448–6453.
10.1073/pnas.95.11.6448
Lambert, M. P., Viola, K. L., Chromy, B. A., Chang, L., Morgan, T. E., Yu, J., Venton, D. L., Krafft, G. A., Finch, C. E., & Klein, W. L. (2001). Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. Journal of Neurochemistry, 79(3), 595–605.
10.1046/j.1471-4159.2001.00592.x
Landau, S. M., Mintun, M. A., Joshi, A. D., Koeppe, R. A., Petersen, R. C., Aisen, P. S., Weiner, M. W., & Jagust, W. J. (2012). Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Annals of Neurology, 72(4), 578–586.
10.1002/ana.23650
Lardinois, O., Kirby, P. J., Morgan, D. L., Sills, R. C., Tomer, K. B., & Deterding, L. J. (2014). Mass spectrometric analysis of rat cerebrospinal fluid proteins following exposure to the neurotoxicant carbonyl sulfide. Rapid Communications in Mass Spectrometry, 28(23), 2531–2538.
10.1002/rcm.7046
Le Bastard, N., Coart, E., Vanderstichele, H., Vanmechelen, E., Martin, J. J., & Engelborghs, S. (2013). Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia. Journal of Alzheimer's Disease, 33(1), 117-31.
10.3233/JAD-2012-121246
Lee, A. G. (2003). Lipid-protein interactions in biological membranes: A structural perspective. Biochimica Et Biophysica Acta, 1612(1), 1–40.
10.1016/s0005-2736(03)00056-7
Lee, J.-H., Yu, W. H., Kumar, A., Lee, S., Mohan, P. S., Peterhoff, C. M., Wolfe, D. M., Martinez-Vicente, M., Massey, A. C., Sovak, G., Uchiyama, Y., Westaway, D., Cuervo, A. M., & Nixon, R. A. (2010). Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell, 141(7), 1146–1158.
10.1016/j.cell.2010.05.008
Lesne, J., Chang, H.-J., De Visch, A., et al. (2019). Structural basis for chemically-induced homodimerization of a single domain antibody. Scientific Reports, 9, 1840.
10.1038/s41598-019-38752-y
Leuzy, A., Mattsson-Carlgren, N., Palmqvist, S., Janelidze, S., Dage, J. L., & Hansson, O. (2022). Blood-based biomarkers for Alzheimer’s disease. EMBO Molecular Medicine, 14(1), e14408.
10.15252/emmm.202114408
Lewczuk, P., Matzen, A., Blennow, K., Parnetti, L., Molinuevo, J. L., Eusebi, P., Kornhuber, J., Morris, J. C., & Fagan, A. M. (2017). Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease. Journal of Alzheimer's Disease, 55(2), 813-822.
10.3233/JAD-160722
Li, G., Bien-Ly, N., Andrews-Zwilling, Y., Xu, Q., Bernardo, A., Ring, K., Halabisky, B., Deng, C., Mahley, R. W., & Huang, Y. (2009). GABAergic interneuron dysfunction impairs hippocampal neurogenesis in adult apolipoprotein E4 knockin mice. Cell Stem Cell, 5(6), 634–645.
10.1016/j.stem.2009.10.015
Li, S., Hong, S., Shepardson, N. E., Walsh, D. M., Shankar, G. M., & Selkoe, D. (2009). Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron, 62(6), 788–801.
10.1016/j.neuron.2009.05.012
Li, T., Vandesquille, M., Koukouli, F., Dudeffant, C., Youssef, I., Lenormand, P., Ganneau, C., Maskos, U., Czech, C., Grueninger, F., Duyckaerts, C., Dhenain, M., Bay, S., Delatour, B., & Lafaye, P. (2016). Camelid single-domain antibodies: A versatile tool for in vivo imaging of extracellular and intracellular brain targets. Journal of Controlled Release, 243, 1–10.
10.1016/j.jconrel.2016.09.019
Li, X., An, W.-L., Alafuzoff, I., Soininen, H., Winblad, B., & Pei, J.-J. (2004). Phosphorylated eukaryotic translation factor 4E is elevated in Alzheimer brain. Neuroreport, 15(14), 2237–2240.
10.1097/00001756-200410050-00019
Lin, H., Bhatia, R., & Lal, R. (2001). Amyloid beta protein forms ion channels: Implications for Alzheimer’s disease pathophysiology. FASEB Journal, 15(13), 2433–2444.
10.1096/fj.01-0377com
Lin, M. S., Chen, L. Y., Wang, S. S. S., Chang, Y., & Chen, W. Y. (2008). Examining the levels of ganglioside and cholesterol in cell membrane on attenuation the cytotoxicity of beta-amyloid peptide. Colloids and Surfaces. B, Biointerfaces, 65(2), 172–177.
10.1016/j.colsurfb.2008.03.012
Liu, C. C., Liu, C. C., Kanekiyo, T., Xu, H., & Bu, G. (2013). Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nature Reviews. Neurology, 9(2), 106–118.
10.1038/nrneurol.2012.263
Liu, P., Li, L., He, F., Meng, F., Liu, X., Su, Y., Su, X., Luo, B., & Peng, G. (2023). Identification of Candidate Biomarkers of Alzheimer’s Disease via Multiplex Cerebrospinal Fluid and Serum Proteomics. International Journal of Molecular Sciences, 24(18), 14225.
10.3390/ijms241814225
Lo, R. Y., Hubbard, A. E., Shaw, L. M., Trojanowski, J. Q., Petersen, R. C., Aisen, P. S., Weiner, M. W., & Jagust, W. J. (2011). Longitudinal change of biomarkers in cognitive decline. Archives of Neurology, 68(10), 1257–1266.
10.1001/archneurol.2011.123
Lopez Salon, M., Pasquini, L., Besio Moreno, M., Pasquini, J. M., & Soto, E. (2003). Relationship between beta-amyloid degradation and the 26S proteasome in neural cells. Experimental Neurology, 180(2), 131–143.
10.1016/s0014-4886(02)00060-2
Löppönen, M., Räihä, I., Isoaho, R., Vahlberg, T., & Kivelä, S.-L. (2003). Diagnosing cognitive impairment and dementia in primary healthcare—A more active approach is needed. Age and Ageing, 32(6), 606–612.
10.1093/ageing/afg097
Love, S., & Miners, J. S. (2016). Cerebrovascular disease in ageing and Alzheimer’s disease. Acta Neuropathologica, 131, 645–658.
10.1007/s00401-015-1522-0
Lu, R. C., Tan, M. S., Wang, H., Xie, A. M., Yu, J. T., & Tan, L. (2014). Heat shock protein 70 in Alzheimer’s disease. BioMed Research International, 2014, 435203.
10.1155/2014/435203
Lusardi, T. A., Phillips, J. I., Wiedrick, J. T., Harrington, C. A., Lind, B., Lapidus, J. A., Quinn, J. F., & Saugstad, J. A. (2017). MicroRNAs in Human Cerebrospinal Fluid as Biomarkers for Alzheimer’s Disease. Journal of Alzheimer’s Disease: JAD, 55(3), 1223–1233.
10.3233/JAD-160835
Manoutcharian, K., Acero, G., Munguia, M. E., Becerril, B., Massieu, L., Govezensky, T., Ortiz, E., Marks, J. D., Cao, C., Ugen, K., & Gevorkian, G. (2004). Human single chain Fv antibodies and a complementarity determining region-derived peptide binding to amyloid-beta 1-42. Neurobiology of Disease, 17(1), 114–121.
10.1016/j.nbd.2004.06.005
Marín-Argany, M., Rivera-Hernández, G., Martí, J., & Villegas, S. (2011). An anti-Aβ (amyloid β) single-chain variable fragment prevents amyloid fibril formation and cytotoxicity by withdrawing Aβ oligomers from the amyloid pathway. The Biochemical Journal, 437(1), 25–34.
10.1042/BJ20101712
Martinez-Lopez, N., Athonvarangkul, D., & Singh, R. (2015). Autophagy and aging. Advances in Experimental Medicine and Biology, 847, 73–87.
10.1007/978-1-4939-2404-2_3
Mason, R. P., Shoemaker, W. J., Shajenko, L., Chambers, T. E., & Herbette, L. G. (1992). Evidence for changes in the Alzheimer’s disease brain cortical membrane structure mediated by cholesterol. Neurobiology of Aging, 13(3), 413–419.
10.1016/0197-4580(92)90116-f
Mastrogiacoma, F., Lindsay, J. G., Bettendorff, L., Rice, J., & Kish, S. J. (1996). Brain protein and alpha-ketoglutarate dehydrogenase complex activity in Alzheimer’s disease. Annals of Neurology, 39(5), 592–598.
10.1002/ana.410390508
Matsuzaki, K. (2007). Physicochemical interactions of amyloid beta-peptide with lipid bilayers. Biochimica Et Biophysica Acta, 1768(8), 1935–1942.
10.1016/j.bbamem.2007.02.009
Matsuzaki, K., Kato, K., & Yanagisawa, K. (2010). Abeta polymerization through interaction with membrane gangliosides. Biochimica Et Biophysica Acta, 1801(8), 868–877.
10.1016/j.bbalip.2010.01.008
Mattson, M. P. (2004). Pathways towards and away from Alzheimer’s disease. Nature, 430(7000), 631–639.
10.1038/nature02621
Mattson, M. P., Cheng, B., Davis, D., Bryant, K., Lieberburg, I., & Rydel, R. E. (1992). Beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. Journal of Neuroscience, 12(2), 376–389.
10.1523/JNEUROSCI.12-02-00376.1992
Mattsson, N., Zetterberg, H., Hansson, O., Andreasen, N., Parnetti, L., Jonsson, M., Herukka, S.-K., van der Flier, W. M., Blankenstein, M. A., Ewers, M., Rich, K., Kaiser, E., Verbeek, M., Tsolaki, M., Mulugeta, E., Rosén, E., Aarsland, D., Visser, P. J., Schröder, J., … Blennow, K. (2009). CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA, 302(4), 385–393.
10.1001/jama.2009.1064
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J. P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., Bayston, A., Beach, T. G., Blanc, F., Bohnen, N., Bonanni, L., Bras, J., Brundin, P., Burn, D., et al. (2017). Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology, 89(1), 88-100.
10.1212/WNL.0000000000004058
G. M. McKhann, D. S. Knopman, H. Chertkow, B. T. Hyman, C. R. Jack Jr, C. H. Kawas, W. E. Klunk, W. J. Koroshetz, J. J. Manly, R. Mayeux, R. C. Mohs, J. C. Morris, M. N. Rossor, P. Scheltens, M. C. Carrillo, B. Thies, S. Weintraub, & C. H. Phelps. Alzheimer’s & Dementia, 7(3):263-9
10.1016/j.jalz.2011.03.005
McKinnon, C., & Tabrizi, S. J. (2014). The ubiquitin-proteasome system in neurodegeneration. Antioxidants & Redox Signaling, 21(17), 2302–2321.
10.1089/ars.2013.5802
McLaurin, J., Franklin, T., Fraser, P. E., & Chakrabartty, A. (1998). Structural transitions associated with the interaction of Alzheimer beta-amyloid peptides with gangliosides. Journal of Biological Chemistry, 273(8), 4506–4515.
10.1074/jbc.273.8.4506
Mendez, M. F. (2017). Early-Onset Alzheimer Disease. Neurologic Clinics, 35(2), 263–281.
10.1016/j.ncl.2017.01.005
Miao, J., Ma, H., Yang, Y., Liao, Y., Lin, C., Zheng, J., Yu, M., & Lan, J. (2023). Microglia in Alzheimer’s disease: Pathogenesis, mechanisms, and therapeutic potentials. Frontiers in Aging Neuroscience, 15, 1201982.
10.3389/fnagi.2023.1201982
Miao, W. (2008). Electrogenerated chemiluminescence and its biorelated applications. Chemical Reviews, 108(7), 2506–2553.
10.1021/cr068083a
Micsonai, A., Wien, F., Bulyáki, É., Kun, J., Moussong, É., Lee, Y.-H., Goto, Y., Réfrégiers, M., & Kardos, J. (2018). BeStSel: A web server for accurate protein secondary structure prediction and fold recognition from the circular dichroism spectra. Nucleic Acids Research, 46(W1), W315–W322.
10.1093/nar/gky497
Mielke, M. M., & Fowler, N. R. (2024). Alzheimer disease blood biomarkers: Considerations for population-level use. Nature Reviews. Neurology, 20(8), 495–504.
10.1038/s41582-024-00989-1
Milstein, C. (1980). Monoclonal antibodies. Scientific American, 243(4), 66–74.
10.1038/scientificamerican1080-66
Mormino, E. C., Kluth, J. T., Madison, C. M., Rabinovici, G. D., Baker, S. L., Miller, B. L., Koeppe, R. A., Mathis, C. A., Weiner, M. W., & Jagust, W. J. (2009). Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain, 132(Pt 5), 1310–1323.
10.1093/brain/awn320
Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. Journal of Immunological Methods, 65(1–2), 55–63.
10.1016/0022-1759(83)90303-4
Murakami, K. (2014). Conformation-specific antibodies to target amyloid β oligomers and their application to immunotherapy for Alzheimer’s disease. Bioscience, Biotechnology, and Biochemistry, 78(8), 1293–1305.
10.1080/09168451.2014.940275
Muyldermans, S. (2013). Nanobodies: Natural single-domain antibodies. Annual Review of Biochemistry, 82, 775–797.
10.1146/annurev-biochem-063011-092449
Nakashima-Yasuda, H., Uryu, K., Robinson, J., Xie, S. X., Hurtig, H., Duda, J. E., Arnold, S. E., Siderowf, A., Grossman, M., Leverenz, J. B., Woltjer, R., Lopez, O. L., Hamilton, R., Tsuang, D. W., Galasko, D., Masliah, E., Kaye, J., Clark, C. M., Montine, T. J., … Trojanowski, J. Q. (2007). Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathologica, 114(3), 221–229.
10.1007/s00401-007-0261-2
Nalivaeva, N. N., & Turner, A. J. (2013). The amyloid precursor protein: A biochemical enigma in brain development, function and disease. FEBS Letters, 587(13), 2046–2054.
10.1016/j.febslet.2013.05.010
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., Boone, K., Miller, B. L., Cummings, J., & Benson, D. F. (1998). Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology, 51(6), 1546–1554.
10.1212/wnl.51.6.1546
Nebes, R. D. (1989). Semantic memory in Alzheimer’s disease. Psychological Bulletin, 106(3), 377–394.
10.1037/0033-2909.106.3.377
Nicolson, G. L. (2014). The Fluid-Mosaic Model of Membrane Structure: Still relevant to understanding the structure, function and dynamics of biological membranes after more than 40 years. Biochimica Et Biophysica Acta, 1838(6), 1451–1466.
10.1016/j.bbamem.2013.10.019
Nikolaev, A., McLaughlin, T., O’Leary, D. D. M., & Tessier-Lavigne, M. (2009). APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature, 457(7232), 981–989.
10.1038/nature07767
Nisbet, R. M., Nigro, J., Breheney, K., Caine, J., Hattarki, M. K., & Nuttall, S. D. (2013). Central amyloid-β-specific single chain variable fragment ameliorates Aβ aggregation and neurotoxicity. Protein Engineering, Design & Selection, 26(10), 571–580.
10.1093/protein/gzt025
Nonaka, T., Masuda-Suzukake, M., & Hasegawa, M. (2018). Molecular mechanisms of the co-deposition of multiple pathological proteins in neurodegenerative diseases. Neuropathology, 38(1), 64–71.
10.1111/neup.12427
Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E. K., Jones, P. K., Ghanbari, H., Wataya, T., Shimohama, S., Chiba, S., Atwood, C. S., Petersen, R. B., & Smith, M. A. (2001). Oxidative damage is the earliest event in Alzheimer disease. Journal of Neuropathology and Experimental Neurology, 60(8), 759–767.
10.1093/jnen/60.8.759
Nyhus, C., Pihl, M., Hyttel, P., & Hall, V. (2019). Evidence for nucleolar dysfunction in Alzheimer’s disease. Reviews in the Neurosciences, 30(7), 685–700.
10.1515/revneuro-2018-0104
Obregon, D., Hou, H., Deng, J., Giunta, B., Tian, J., Darlington, D., Shahaduzzaman, M., Zhu, Y., Mori, T., Mattson, M. P., & Tan, J. (2012). Soluble amyloid precursor protein-α modulates β-secretase activity and amyloid-β generation. Nature Communications, 3, 777.
10.1038/ncomms1781
O’Connor, A., Karikari, T. K., Poole, T., Ashton, N. J., Lantero Rodriguez, J., Khatun, A., Swift, I., Heslegrave, A. J., Abel, E., Chung, E., Weston, P. S. J., Pavisic, I. M., Ryan, N. S., Barker, S., Rossor, M. N., Polke, J. M., Frost, C., Mead, S., Blennow, K., … Fox, N. C. (2021). Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer’s disease: A longitudinal cohort study. Molecular Psychiatry, 26(10), 5967–5976.
10.1038/s41380-020-0838-x
Olsson, B., Alberg, L., Cullen, N. C., Michael, E., Wahlgren, L., Kroksmark, A.-K., Rostasy, K., Blennow, K., Zetterberg, H., & Tulinius, M. (2019). NFL is a marker of treatment response in children with SMA treated with nusinersen. Journal of Neurology, 266(9), 2129–2136.
10.1007/s00415-019-09389-8
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., Wu, E., Dakin, K., Petzold, M., Blennow, K., & Zetterberg, H. (2016). CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: A systematic review and meta-analysis. The Lancet Neurology, 15(7), 673–684.
10.1016/S1474-4422(16)00070-3
Ossenkoppele, R., Rabinovici, G. D., Smith, R., Cho, H., Schöll, M., Strandberg, O., Palmqvist, S., Mattsson, N., Janelidze, S., Santillo, A., Ohlsson, T., Jögi, J., Tsai, R., La Joie, R., Kramer, J., Boxer, A. L., Gorno-Tempini, M. L., Miller, B. L., Choi, J. Y., … Hansson, O. (2018). Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA, 320(11), 1151–1162.
10.1001/jama.2018.12917
Ostrowitzki, S., Bittner, T., Sink, K. M., Mackey, H., Rabe, C., Honig, L. S., Cassetta, E., Woodward, M., Boada, M., van Dyck, C. H., Grimmer, T., Selkoe, D. J., Schneider, A., Blondeau, K., Hu, N., Quartino, A., Clayton, D., Dolton, M., Dang, Y., … Doody, R. S. (2022). Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials. JAMA Neurology, 79(11), 1113–1121.
10.1001/jamaneurol.2022.2909
S. Ostrowitzki, D. Deptula, L. Thurfjell, F. Barkhof, B. Bohrmann, D. J. Brooks, W. E. Klunk, E. Ashford, K. Yoo, Z. X. Xu, H. Loetscher, & L. Santarelli. Archives of Neurology, 69(2):198-207
10.1001/archneurol.2011.1538
Ovod, V., Ramsey, K. N., Mawuenyega, K. G., Bollinger, J. G., Hicks, T., Schneider, T., Sullivan, M., Paumier, K., Holtzman, D. M., Morris, J. C., Benzinger, T., Fagan, A. M., Patterson, B. W., & Bateman, R. J. (2017). Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimer’s & Dementia, 13(8), 841–849.
10.1016/j.jalz.2017.06.2266
Pain, C., Dumont, J., & Dumoulin, M. (2015). Camelid single-domain antibody fragments: Uses and prospects to investigate protein misfolding and aggregation, and to treat diseases associated with these phenomena. Biochimie, 111, 82–106.
10.1016/j.biochi.2015.01.012
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., Mattsson-Carlgren, N., Strandberg, O., Smith, R., Villegas, A., Sepulveda-Falla, D., Chai, X., Proctor, N. K., Beach, T. G., Blennow, K., … Hansson, O. (2020). Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA, 324(8), 772–781.
10.1001/jama.2020.12134
Pannee, J., Shaw, L. M., Korecka, M., Waligorska, T., Teunissen, C. E., Stoops, E., Vanderstichele, H. M. J., Mauroo, K., Verberk, I. M. W., Keshavan, A., Pesini, P., Sarasa, L., Pascual-Lucas, M., Fandos, N., Allué, J.-A., Portelius, E., Andreasson, U., Yoda, R., Nakamura, A., … Zetterberg, H. (2021). The global Alzheimer’s Association round robin study on plasma amyloid β methods. Alzheimer’s & Dementia (Amsterdam, Netherlands), 13(1), e12242.
10.1002/dad2.12242
Panza, F., Lozupone, M., Seripa, D., & Imbimbo, B. P. (2019). Amyloid-β immunotherapy for alzheimer disease: Is it now a long shot? Annals of Neurology, 85(3), 303–315.
10.1002/ana.25410
Paravastu, A. K., Leapman, R. D., Yau, W.-M., & Tycko, R. (2008). Molecular structural basis for polymorphism in Alzheimer’s beta-amyloid fibrils. Proceedings of the National Academy of Sciences, 105(47), 18349–18354.
10.1073/pnas.0806270105
Parker, W. D., Filley, C. M., & Parks, J. K. (1990). Cytochrome oxidase deficiency in Alzheimer’s disease. Neurology, 40(8), 1302–1303.
10.1212/wnl.40.8.1302
Perchiacca, J. M., Ladiwala, A. R. A., Bhattacharya, M., & Tessier, P. M. (2012). Structure-based design of conformation- and sequence-specific antibodies against amyloid β. Proceedings of the National Academy of Sciences, 109(1), 84–89.
10.1073/pnas.1111232108
Pereira, C., Santos, M. S., & Oliveira, C. (1998). Mitochondrial function impairment induced by amyloid beta-peptide on PC12 cells. Neuroreport, 9(8), 1749–1755.
10.1097/00001756-199806010-00015
Perrin, R. J., Fagan, A. M., & Holtzman, D. M. (2009). Multimodal techniques for diagnosis and prognosis of Alzheimer’s disease. Nature, 461(7266), 916–922.
10.1038/nature08538
Perry, R. J., & Hodges, J. R. (1999). Attention and executive deficits in Alzheimer’s disease. A critical review. Brain, 122 ( Pt 3), 383–404.
10.1093/brain/122.3.383
Peters, C., Espinoza, M. P., Gallegos, S., Opazo, C., & Aguayo, L. G. (2015). Alzheimer’s Aβ interacts with cellular prion protein inducing neuronal membrane damage and synaptotoxicity. Neurobiology of Aging, 36(3), 1369–1377.
10.1016/j.neurobiolaging.2014.11.019
Pickford, F., Masliah, E., Britschgi, M., Lucin, K., Narasimhan, R., Jaeger, P. A., Small, S., Spencer, B., Rockenstein, E., Levine, B., & Wyss-Coray, T. (2008). The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid-beta accumulation in mice. Journal of Clinical Investigation, 118(6), 2190–2199.
10.1172/JCI33585
Pietrzak, M., Rempala, G., Nelson, P. T., Zheng, J.-J., & Hetman, M. (2011). Epigenetic silencing of nucleolar rRNA genes in Alzheimer’s disease. PloS One, 6(7), e22585.
10.1371/journal.pone.0022585
Pollard, H. B., Rojas, E., & Arispe, N. (1993). A New Hypothesis for the Mechanism of Amyloid Toxicity, Based on the Calcium Channel Activity of Amyloid Protein (A P) in Phospholipid Bilayer Membranes. Annals of the New York Academy of Sciences, 695, 165–168.
10.1111/j.1749-6632.1993.tb23044.x
Popugaeva, E., Pchitskaya, E., & Bezprozvanny, I. (2018). Dysregulation of Intracellular Calcium Signaling in Alzheimer’s Disease. Antioxidants & Redox Signaling, 29(12), 1176–1188.
10.1089/ars.2018.7506
Praticò, D. (2008). Oxidative stress hypothesis in Alzheimer’s disease: A reappraisal. Trends in Pharmacological Sciences, 29(12), 609–615.
10.1016/j.tips.2008.09.001
Rabinovici, G. D. (2019). Late-onset Alzheimer Disease. Continuum (Minneapolis, Minn.), 25(1), 14–33.
10.1212/CON.0000000000000700
Rai, S. N., Singh, C., Singh, A., Singh, M. P., & Singh, B. K. (2020). Mitochondrial Dysfunction: A Potential Therapeutic Target to Treat Alzheimer’s Disease. Molecular Neurobiology, 57(7), 3075–3088.
10.1007/s12035-020-01945-y
Rasmussen, M. K., Mestre, H., & Nedergaard, M. (2018). The glymphatic pathway in neurological disorders. The Lancet Neurology, 17(11), 1016–1024.
10.1016/S1474-4422(18)30318-1
Reed, B. R., Mungas, D., Farias, S. T., Harvey, D., Beckett, L., Widaman, K., Hinton, L., & DeCarli, C. (2010). Measuring cognitive reserve based on the decomposition of episodic memory variance. Brain, 133(Pt 8), 2196–2209.
10.1093/brain/awq154
Reese, L. C., & Taglialatela, G. A. (2011). Role for calcineurin in Alzheimer’s disease. Current Neuropharmacology, 9(4), 685–692.
10.2174/156802611798192661
Reiman, E. M., Quiroz, Y. T., Fleisher, A. S., Chen, K., Velez-Pardo, C., Jimenez-Del-Rio, M., Fagan, A. M., Shah, A. R., Alvarez, S., Arbelaez, A., Giraldo, M., Acosta-Baena, N., Sperling, R. A., Dickerson, B., Stern, C. E., Tirado, V., Munoz, C., Reiman, R. A., Huentelman, M. J., … Lopera, F. (2012). Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer’s disease in the presenilin 1 E280A kindred: A case-control study. The Lancet Neurology, 11(12), 1048–1056.
10.1016/S1474-4422(12)70228-4
Reiss, A. B., Arain, H. A., Stecker, M. M., Siegart, N. M., & Kasselman, L. J. (2018). Amyloid toxicity in Alzheimer’s disease. Reviews in the Neurosciences, 29(6), 613–627.
10.1515/revneuro-2017-0063
Relkin, N., Marmarou, A., Klinge, P., Bergsneider, M., & Black, P. M. (2005). Diagnosing idiopathic normal-pressure hydrocephalus. Neurosurgery, 57(3 Suppl), S4-16.
10.1227/01.neu.0000168185.29659.c5
Renner, J. A., Burns, J. M., Hou, C. E., McKeel, D. W., Storandt, M., & Morris, J. C. (2004). Progressive posterior cortical dysfunction: A clinicopathologic series. Neurology, 63(7), 1175–1180.
10.1212/01.wnl.0000140290.80962.bf
Revi, M. (2020). Alzheimer’s Disease Therapeutic Approaches. Advances in Experimental Medicine and Biology, 1195, 105–116.
10.1007/978-3-030-32633-3_15
Rissin, D. M., Kan, C. W., Campbell, T. G., Howes, S. C., Fournier, D. R., Song, L., Piech, T., Patel, P. P., Chang, L., Rivnak, A. J., Ferrell, E. P., Randall, J. D., Provuncher, G. K., Walt, D. R., & Duffy, D. C. (2010). Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nature Biotechnology, 28(6), 595–599.
10.1038/nbt.1641
Robertson, D. S. (2010). The physical chemistry of brain and neural cell membranes: An overview. Neurochemical Research, 35(5), 681–687.
10.1007/s11064-010-0121-7
Roychaudhuri, R., Yang, M., Hoshi, M. M., & Teplow, D. B. (2009). Amyloid beta-protein assembly and Alzheimer disease. Journal of Biological Chemistry, 284(8), 4749–4753.
10.1074/jbc.R800036200
Rudajev, V., & Novotny, J. (2020). The Role of Lipid Environment in Ganglioside GM1-Induced Amyloid β Aggregation. Membranes, 10(9), 226.
10.3390/membranes10090226
Sachdev, P., Kalaria, R., O’Brien, J., Skoog, I., Alladi, S., Black, S. E., Blacker, D., Blazer, D. G., Chen, C., Chui, H., Ganguli, M., Jellinger, K., Jeste, D. V., Pasquier, F., Paulsen, J., Prins, N., Rockwood, K., Roman, G., Scheltens, P., & Internationlal Society for Vascular Behavioral and Cognitive Disorders. (2014). Diagnostic criteria for vascular cognitive disorders: A VASCOG statement. Alzheimer Disease and Associated Disorders, 28(3), 206–218.
10.1097/WAD.0000000000000034
Saido, T., & Leissring, M. A. (2012). Proteolytic degradation of amyloid β-protein. Cold Spring Harbor Perspectives in Medicine, 2(6), a006379.
10.1101/cshperspect.a006379
Saito, R., Kaneko, M., Kitamura, Y., Takata, K., Kawada, K., Okuma, Y., & Nomura, Y. (2014). Effects of oxidative stress on the solubility of HRD1, a ubiquitin ligase implicated in Alzheimer’s disease. PloS One, 9(5), e94576.
10.1371/journal.pone.0094576
Saito, R., Kaneko, M., Okuma, Y., & Nomura, Y. (2010). Correlation between decrease in protein levels of ubiquitin ligase HRD1 and amyloid-beta production. Journal of Pharmacological Sciences, 113(3), 285–288.
10.1254/jphs.10118sc
Sajdel-Sulkowska, E. M., & Marotta, C. A. (1984). Alzheimer’s disease brain: Alterations in RNA levels and in a ribonuclease-inhibitor complex. Science, 225(4665), 947–949.
10.1126/science.6206567
Sakono, M., & Zako, T. (2010). Amyloid oligomers: Formation and toxicity of Abeta oligomers. The FEBS Journal, 277(6), 1348–1358.
10.1111/j.1742-4658.2010.07568.x
Samad, N., Ishaq, S., Bano, S., & Manzoor, N. (2017). Calcium Regulation in Alzheimer’s Disease: Mechanistic Understanding. Journal of the College of Physicians and Surgeons--Pakistan: JCPSP, 27(9), 566–571.
Santoro, M. M. & Bolen, D. W. Unfolding free energy changes determined by the linear extrapolation method. 1. Unfolding of phenylmethanesulfonyl .alpha.-chymotrypsin using different denaturants. Biochemistry 27, 8063–8068 (1988).
10.1021/bi00421a014
Santos, A. N., Torkler, S., Nowak, D., Schlittig, C., Goerdes, M., Lauber, T., Trischmann, L., Schaupp, M., Penz, M., Tiller, F.-W., & Böhm, G. (2007). Detection of amyloid-beta oligomers in human cerebrospinal fluid by flow cytometry and fluorescence resonance energy transfer. Journal of Alzheimer’s Disease, 11(1), 117–125.
10.3233/jad-2007-11114
Santos, R. X., Correia, S. C., Wang, X., Perry, G., Smith, M. A., Moreira, P. I., & Zhu, X. (2010). A synergistic dysfunction of mitochondrial fission/fusion dynamics and mitophagy in Alzheimer’s disease. Journal of Alzheimer’s Disease, 20 Suppl 2, S401-412.
10.3233/JAD-2010-100666
Savage, M. J., Kalinina, J., Wolfe, A., Tugusheva, K., Korn, R., Cash-Mason, T., Maxwell, J. W., Hatcher, N. G., Haugabook, S. J., Wu, G., Howell, B. J., Renger, J. J., Shughrue, P. J., & McCampbell, A. (2014). A sensitive aβ oligomer assay discriminates Alzheimer’s and aged control cerebrospinal fluid. Journal of Neuroscience, 34(8), 2884–2897.
10.1523/JNEUROSCI.1675-13.2014
Scalia, F., Vitale, A. M., Santonocito, R., Conway de Macario, E., Macario, A. J. L., & Cappello, F. (2021). The Neurochaperonopathies: Anomalies of the Chaperone System with Pathogenic Effects in Neurodegenerative and Neuromuscular Disorders. Applied Sciences, 11(3), 898.
10.3390/app11030898
Schengrund, C. L. (2010). Lipid rafts: Keys to neurodegeneration. Brain Research Bulletin, 82(1–2), 7–17.
10.1016/j.brainresbull.2010.02.013
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, E., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., … Younkin, S. (1996). Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nature Medicine, 2(8), 864–870.
10.1038/nm0896-864
Schneider, J. A., Arvanitakis, Z., Bang, W., & Bennett, D. A. (2007). Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology, 69(24), 2197–2204.
10.1212/01.wnl.0000271090.28148.24
Schwab, C., Arai, T., Hasegawa, M., Yu, S., & McGeer, P. L. (2008). Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease. Journal of Neuropathology and Experimental Neurology, 67(12), 1159–1165.
10.1097/NEN.0b013e31818e8951
Sciacca, M. F. M., La Rosa, C., & Milardi, D. (2021). Amyloid-Mediated Mechanisms of Membrane Disruption. Biophysica, 1(2), 137-156.
10.3390/biophysica1020011
Selkoe, D. J. (1999). Translating cell biology into therapeutic advances in Alzheimer’s disease. Nature, 399(6738 Suppl), A23-31.
10.1038/399a023
Selkoe, D. J. (2019). Alzheimer disease and aducanumab: Adjusting our approach. Nature Reviews. Neurology, 15(7), 365–366.
10.1038/s41582-019-0205-1
Selles, M. C., Fortuna, J. T. S., Cercato, M. C., Santos, L. E., Domett, L., Bitencourt, A. L. B., Carraro, M. F., Souza, A. S., Janickova, H., Azevedo, C. V., Campos, H. C., de Souza, J. M., Alves-Leon, S., Prado, V. F., Prado, M. A. M., Epstein, A. L., Salvetti, A., Longo, B. M., Arancio, O., … Ferreira, S. T. (2023). AAV-mediated neuronal expression of an scFv antibody selective for Aβ oligomers protects synapses and rescues memory in Alzheimer models. Molecular Therapy, 31(2), 409–419.
10.1016/j.ymthe.2022.11.002
Sengupta, U., Guerrero-Muñoz, M. J., Castillo-Carranza, D. L., Lasagna-Reeves, C. A., Gerson, J. E., Paulucci-Holthauzen, A. A., Krishnamurthy, S., Farhed, M., Jackson, G. R., & Kayed, R. (2015). Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies. Biological Psychiatry, 78(10), 672–683.
10.1016/j.biopsych.2014.12.019
Senjem, M. L., Gunter, J. L., Shiung, M. M., Petersen, R. C., & Jack, C. R. (2005). Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease. NeuroImage, 26(2), 600–608.
10.1016/j.neuroimage.2005.02.005
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., O’Gorman, J., Qian, F., Arastu, M., Li, M., Chollate, S., Brennan, M. S., Quintero-Monzon, O., Scannevin, R. H., Arnold, H. M., … Sandrock, A. (2016). The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature, 537(7618), 50–56.
10.1038/nature19323
Shaw, L. M., Vanderstichele, H., Knapik-Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., Dean, R., Siemers, E., Potter, W., Lee, V. M.-Y., Trojanowski, J. Q., & Alzheimer’s Disease Neuroimaging Initiative. (2009). Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Annals of Neurology, 65(4), 403–413.
10.1002/ana.21610
Sheu, K. F., Cooper, A. J., Koike, K., Koike, M., Lindsay, J. G., & Blass, J. P. (1994). Abnormality of the alpha-ketoglutarate dehydrogenase complex in fibroblasts from familial Alzheimer’s disease. Annals of Neurology, 35(3), 312–318.
10.1002/ana.410350311
Sheu, K. F., Kim, Y. T., Blass, J. P., & Weksler, M. E. (1985). An immunochemical study of the pyruvate dehydrogenase deficit in Alzheimer’s disease brain. Annals of Neurology, 17(5), 444–449.
10.1002/ana.410170505
Shughrue, P. J., Acton, P. J., Breese, R. S., Zhao, W.-Q., Chen-Dodson, E., Hepler, R. W., Wolfe, A. L., Matthews, M., Heidecker, G. J., Joyce, J. G., Villarreal, S. A., & Kinney, G. G. (2010). Anti-ADDL antibodies differentially block oligomer binding to hippocampal neurons. Neurobiology of Aging, 31(2), 189–202.
10.1016/j.neurobiolaging.2008.04.003
Simrén, J., Elmgren, A., Blennow, K., & Zetterberg, H. (2023). Fluid biomarkers in Alzheimer’s disease. Advances in Clinical Chemistry, 112, 249–281.
10.1016/bs.acc.2022.09.006
Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., Collins, E. C., Solomon, P., Salloway, S., Apostolova, L. G., Hansson, O., Ritchie, C., Brooks, D. A., Mintun, M., Skovronsky, D. M., & TRAILBLAZER-ALZ 2 Investigators. (2023). Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA, 330(6), 512–527.
10.1001/jama.2023.13239
Sims, R., Hill, M., & Williams, J. (2020). The multiplex model of the genetics of Alzheimer’s disease. Nature Neuroscience, 23(3), 311–322.
10.1038/s41593-020-0599-5
Singer, S. J., & Nicolson, G. L. (1972). The fluid mosaic model of the structure of cell membranes. Science, 175(4023), 720–731.
10.1126/science.175.4023.720
Singh, A., Kukreti, R., Saso, L., & Kukreti, S. (2019). Oxidative Stress: A Key Modulator in Neurodegenerative Diseases. Molecules, 24(8), 1583.
10.3390/molecules24081583
Somavarapu, A. K., & Kepp, K. P. (2015). The Dependence of Amyloid-β Dynamics on Protein Force Fields and Water Models. Chemphyschem, 16(15), 3278–3289.
10.1002/cphc.201500415
Song, S., Kim, S.-Y., Hong, Y.-M., Jo, D.-G., Lee, J.-Y., Shim, S. M., Chung, C.-W., Seo, S. J., Yoo, Y. J., Koh, J.-Y., Lee, M. C., Yates, A. J., Ichijo, H., & Jung, Y.-K. (2003). Essential role of E2-25K/Hip-2 in mediating amyloid-beta neurotoxicity. Molecular Cell, 12(3), 553–563.
10.1016/j.molcel.2003.08.005
Sorbi, S., Bird, E. D., & Blass, J. P. (1983). Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain. Annals of Neurology, 13(1), 72–78.
10.1002/ana.410130116
Sorbi, S., Nacmias, B., Forleo, P., Latorraca, S., Gobbini, I., Bracco, L., Piacentini, S., & Amaducci, L. (1994). ApoE allele frequencies in Italian sporadic and familial Alzheimer’s disease. Neuroscience Letters, 177(1–2), 100–102.
10.1016/0304-3940(94)90054-x
Sormanni, P., Aprile, F. A., & Vendruscolo, M. (2015). Rational design of antibodies targeting specific epitopes within intrinsically disordered proteins. Proceedings of the National Academy of Sciences, 112(32), 9902–9907.
10.1073/pnas.1422401112
Sormanni, P., Aprile, F. A., & Vendruscolo, M. (2018). Third generation antibody discovery methods: In silico rational design. Chemical Society Reviews, 47(24), 9137–9157.
10.1039/c8cs00523k
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison-Bogorad, M., … Phelps, C. H. (2011). Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia, 7(3), 280–292.
10.1016/j.jalz.2011.03.003
Stewart, M. D., Ritterhoff, T., Klevit, R. E., & Brzovic, P. S. (2016). E2 enzymes: More than just middle men. Cell Research, 26(4), 423.
10.1038/cr.2016.35
Strimbu, K., & Tavel, J. A. (2010). What are biomarkers? Current Opinion in HIV and AIDS, 5(6), 463–466.
10.1097/COH.0b013e32833ed177
Sunde, M., & Blake, C. (1997). The structure of amyloid fibrils by electron microscopy and X-ray diffraction. Advances in Protein Chemistry, 50, 123–159.
10.1016/s0065-3233(08)60320-4
Sutphen, C. L., Jasielec, M. S., Shah, A. R., Macy, E. M., Xiong, C., Vlassenko, A. G., Benzinger, T. L. S., Stoops, E. E. J., Vanderstichele, H. M. J., Brix, B., Darby, H. D., Vandijck, M. L. J., Ladenson, J. H., Morris, J. C., Holtzman, D. M., & Fagan, A. M. (2015). Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. JAMA Neurology, 72(9), 1029–1042.
10.1001/jamaneurol.2015.1285
Swanson, C. J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J., Lai, R. Y. K., Lannfelt, L., Bradley, H., Rabe, M., Koyama, A., Reyderman, L., Berry, D. A., Berry, S., Gordon, R., Kramer, L. D., & Cummings, J. L. (2021). A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimer’s Research & Therapy, 13(1), 80.
10.1186/s13195-021-00813-8
Sewell, R. D. E. (Ed.). (2007). Protein Misfolding in Neurodegenerative Diseases: Mechanisms and Therapeutic Strategies. CRC Press.
10.1201/9781420007145
Swerdlow, R. H. (2018). Mitochondria and Mitochondrial Cascades in Alzheimer’s Disease. Journal of Alzheimer’s Disease: JAD, 62(3), 1403–1416.
10.3233/JAD-170585
Taipale, M., Jarosz, D. F., & Lindquist, S. (2010). HSP90 at the hub of protein homeostasis: Emerging mechanistic insights. Nature Reviews. Molecular Cell Biology, 11(7), 515–528.
10.1038/nrm2918
Tcw, J., & Goate, A. M. (2017). Genetics of β-Amyloid Precursor Protein in Alzheimer’s Disease. Cold Spring Harbor Perspectives in Medicine, 7(6), a024539.
10.1101/cshperspect.a024539
Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., Correale, J., Fazekas, F., Filippi, M., Freedman, M. S., Fujihara, K., Galetta, S. L., Hartung, H. P., Kappos, L., Lublin, F. D., Marrie, R. A., Miller, A. E., Miller, D. H., Montalban, X., … Cohen, J. A. (2018). Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology, 17(2), 162–173.
10.1016/S1474-4422(17)30470-2
Tokunaga, Y., & Takeuchi, K. (2020). Role of NMR in High Ordered Structure Characterization of Monoclonal Antibodies. International Journal of Molecular Sciences, 22(1), 46.
10.3390/ijms22010046
Toledo, J. B., Arnold, S. E., Raible, K., Brettschneider, J., Xie, S. X., Grossman, M., Monsell, S. E., Kukull, W. A., & Trojanowski, J. Q. (2013). Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer’s Coordinating Centre. Brain, 136, 2697–2706.
10.1093/brain/awt188
Tu, S., Okamoto, S., Lipton, S. A., & Xu, H. (2014). Oligomeric Aβ-induced synaptic dysfunction in Alzheimer’s disease. Molecular Neurodegeneration, 9, 48.
10.1186/1750-1326-9-48
Twohig, D., & Nielsen, H. M. (2019). α-synuclein in the pathophysiology of Alzheimer’s disease. Molecular Neurodegeneration, 14(1), 23.
10.1186/s13024-019-0320-x
Vadukul, D. M., Papp, M., Thrush, R. J., Wang, J., Jin, Y., Arosio, P., & Aprile, F. A. (2023). α-Synuclein Aggregation Is Triggered by Oligomeric Amyloid-β 42 via Heterogeneous Primary Nucleation. Journal of the American Chemical Society, 145(33), 18276–18285.
10.1021/jacs.3c03212
Valdor, R., Mocholi, E., Botbol, Y., Guerrero-Ros, I., Chandra, D., Koga, H., Gravekamp, C., Cuervo, A. M., & Macian, F. (2014). Chaperone-mediated autophagy regulates T cell responses through targeted degradation of negative regulators of T cell activation. Nature Immunology, 15(11), 1046–1054.
10.1038/ni.3003
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., Froelich, L., Katayama, S., Sabbagh, M., Vellas, B., Watson, D., Dhadda, S., Irizarry, M., Kramer, L. D., & Iwatsubo, T. (2023). Lecanemab in Early Alzheimer’s Disease. The New England Journal of Medicine, 388(1), 9–21.
10.1056/NEJMoa2212948
Veerabhadrappa, B., Delaby, C., Hirtz, C., Vialaret, J., Alcolea, D., Lleó, A., Fortea, J., Santosh, M. S., Choubey, S., & Lehmann, S. (2020). Detection of amyloid beta peptides in body fluids for the diagnosis of alzheimer’s disease: Where do we stand? Critical Reviews in Clinical Laboratory Sciences, 57(2), 99–113.
10.1080/10408363.2019.1678011
Vemuri, P., Weigand, S. D., Przybelski, S. A., Knopman, D. S., Smith, G. E., Trojanowski, J. Q., Shaw, L. M., Decarli, C. S., Carmichael, O., Bernstein, M. A., Aisen, P. S., Weiner, M., Petersen, R. C., & Jack, C. R. (2011). Cognitive reserve and Alzheimer’s disease biomarkers are independent determinants of cognition. Brain, 134(Pt 5), 1479–1492.
10.1093/brain/awr049
Vemuri, P., Wiste, H. J., Weigand, S. D., Shaw, L. M., Trojanowski, J. Q., Weiner, M. W., Knopman, D. S., Petersen, R. C., & Jack, C. R. (2009). MRI and CSF biomarkers in normal, MCI, and AD subjects: Predicting future clinical change. Neurology, 73(4), 294–301.
10.1212/WNL.0b013e3181af79fb
Vermunt, L., Sikkes, S. A. M., van den Hout, A., Handels, R., Bos, I., van der Flier, W. M., Kern, S., Ousset, P.-J., Maruff, P., Skoog, I., Verhey, F. R. J., Freund-Levi, Y., Tsolaki, M., Wallin, Å. K., Olde Rikkert, M., Soininen, H., Spiru, L., Zetterberg, H., Blennow, K., … ICTUS/DSA study groups. (2019). Duration of preclinical, prodromal, and dementia stages of Alzheimer’s disease in relation to age, sex, and APOE genotype. Alzheimer’s & Dementia, 15(7), 888–898.
10.1016/j.jalz.2019.04.001
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., Ames, D., Rowe, C. C., Masters, C. L., & Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. (2013). Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: A prospective cohort study. The Lancet Neurology, 12(4), 357–367.
10.1016/S1474-4422(13)70044-9
Villemagne, V. L., Pike, K. E., Chételat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., Ackermann, U., Jones, G., Szoeke, C., Salvado, O., Martins, R., O’Keefe, G., Mathis, C. A., Klunk, W. E., Ames, D., Masters, C. L., & Rowe, C. C. (2011). Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Annals of Neurology, 69(1), 181–192.
10.1002/ana.22248
Vivekanandan, S., Brender, J. R., Lee, S. Y., & Ramamoorthy, A. (2011). A partially folded structure of amyloid-beta(1-40) in an aqueous environment. Biochemical and Biophysical Research Communications, 411(2), 312–316.
10.1016/j.bbrc.2011.06.133
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002). Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature, 416(6880), 535–539.
10.1038/416535a
Walsh, D. M., & Selkoe, D. J. (2004). Deciphering the molecular basis of memory failure in Alzheimer’s disease. Neuron, 44(1), 181–193.
10.1016/j.neuron.2004.09.010
Walsh, D. M., Tseng, B. P., Rydel, R. E., Podlisny, M. B., & Selkoe, D. J. (2000). The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry, 39(35), 10831–10839.
10.1021/bi001048s
Wang, H.-W., Pasternak, J. F., Kuo, H., Ristic, H., Lambert, M. P., Chromy, B., Viola, K. L., Klein, W. L., Stine, W. B., Krafft, G. A., & Trommer, B. L. (2002). Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Research, 924(2), 133–140.
10.1016/s0006-8993(01)03058-x
Wang, X., Wang, W., Li, L., Perry, G., Lee, H., & Zhu, X. (2014). Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease. Biochimica Et Biophysica Acta, 1842(8), 1240–1247.
10.1016/j.bbadis.2013.10.015
Wasik, U., Schneider, G., Mietelska-Porowska, A., Mazurkiewicz, M., Fabczak, H., Weis, S., Zabke, C., Harrington, C. R., Filipek, A., & Niewiadomska, G. (2013). Calcyclin binding protein and Siah-1 interacting protein in Alzheimer’s disease pathology: Neuronal localization and possible function. Neurobiology of Aging, 34(5), 1380–1388.
10.1016/j.neurobiolaging.2012.11.007
Wasmer, C., Lange, A., Van Melckebeke, H., Siemer, A. B., Riek, R., & Meier, B. H. (2008). Amyloid fibrils of the HET-s(218-289) prion form a beta solenoid with a triangular hydrophobic core. Science, 319(5869), 1523–1526.
10.1126/science.1151839
Weintraub, S., Wicklund, A. H., & Salmon, D. P. (2012). The neuropsychological profile of Alzheimer disease. Cold Spring Harbor Perspectives in Medicine, 2(4), a006171.
10.1101/cshperspect.a006171
Westermark, P. (2005). Aspects on human amyloid forms and their fibril polypeptides. The FEBS Journal, 272(23), 5942–5949.
10.1111/j.1742-4658.2005.05024.x
Westin, K., Buchhave, P., Nielsen, H., Minthon, L., Janciauskiene, S., & Hansson, O. (2012). CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer’s disease. PloS One, 7(1), e30525.
10.1371/journal.pone.0030525
Whitehouse, P. J., Orgogozo, J. M., Becker, R. E., Gauthier, S., Pontecorvo, M., Erzigkeit, H., Rogers, S., Mohs, R. C., Bodick, N., Bruno, G., & Dal-Bianco, P. (1997). Quality-of-life assessment in dementia drug development. Alzheimer Disease and Associated Disorders, 11 Suppl 3, 56–60.
Wiatrak, B., Piasny, J., Kuźniarski, A., & Gąsiorowski, K. (2021). Interactions of Amyloid-β with Membrane Proteins. International Journal of Molecular Sciences, 22(11), 6075.
10.3390/ijms22116075
Wiedrick, J. T., Phillips, J. I., Lusardi, T. A., McFarland, T. J., Lind, B., Sandau, U. S., Harrington, C. A., Lapidus, J. A., Galasko, D. R., Quinn, J. F., & Saugstad, J. A. (2019). Validation of MicroRNA Biomarkers for Alzheimer’s Disease in Human Cerebrospinal Fluid. Journal of Alzheimer’s Disease: JAD, 67(3), 875–891.
10.3233/JAD-180539
Wilkins, H. M., & Swerdlow, R. H. (2017). Amyloid precursor protein processing and bioenergetics. Brain Research Bulletin, 133, 71–79.
10.1016/j.brainresbull.2016.08.009
Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., Fratiglioni, L., Frisoni, G. B., Gauthier, S., Georges, J., Graff, C., Iqbal, K., Jessen, F., Johansson, G., Jönsson, L., … Zetterberg, H. (2016). Defeating Alzheimer’s disease and other dementias: A priority for European science and society. The Lancet Neurology, 15(5), 455–532.
10.1016/S1474-4422(16)00062-4
Wojdała, A. L., Bellomo, G., Toja, A., Gaetani, L., Parnetti, L., & Chiasserini, D. (2024). CSF and plasma Aβ42/40 across Alzheimer’s disease continuum: Comparison of two ultrasensitive Simoa® assays targeting distinct amyloid regions. Clinical Chemistry and Laboratory Medicine, 62(2), 332–340.
10.1515/cclm-2023-0659
World Health Organization. (2021). Fact sheets of dementia. who.int
Yamamoto, N., Fukata, Y., Fukata, M., & Yanagisawa, K. (2007). GM1-ganglioside-induced Abeta assembly on synaptic membranes of cultured neurons. Biochimica Et Biophysica Acta, 1768(5), 1128–1137.
10.1016/j.bbamem.2007.01.009
Yamazaki, T., Koo, E. H., & Selkoe, D. J. (1997). Cell surface amyloid beta-protein precursor colocalizes with beta 1 integrins at substrate contact sites in neural cells. Journal of Neuroscience, 17(3), 1004–1010.
10.1523/JNEUROSCI.17-03-01004.1997
Yanagisawa, K. (2007). Role of gangliosides in Alzheimer’s disease. Biochimica Et Biophysica Acta, 1768(8), 1943–1951.
10.1016/j.bbamem.2007.01.018
Yang, T., O’Malley, T. T., Kanmert, D., Jerecic, J., Zieske, L. R., Zetterberg, H., Hyman, B. T., Walsh, D. M., & Selkoe, D. J. (2015). A highly sensitive novel immunoassay specifically detects low levels of soluble Aβ oligomers in human cerebrospinal fluid. Alzheimer’s Research & Therapy, 7(1), 14.
10.1186/s13195-015-0100-y
Yerbury, J. J., & Wilson, M. R. (2010). Extracellular chaperones modulate the effects of Alzheimer’s patient cerebrospinal fluid on Abeta(1-42) toxicity and uptake. Cell Stress & Chaperones, 15(1), 115–121.
10.1007/s12192-009-0122-0
Yoshihara, T., Takiguchi, S., Kyuno, A., Tanaka, K., Kuba, S., Hashiguchi, S., Ito, Y., Hashimoto, T., Iwatsubo, T., Tsuyama, S., Nakashima, T., & Sugimura, K. (2008). Immunoreactivity of phage library-derived human single-chain antibodies to amyloid beta conformers in vitro. Journal of Biochemistry, 143(4), 475–486.
10.1093/jb/mvm239
Young-Pearse, T. L., Chen, A. C., Chang, R., Marquez, C., & Selkoe, D. J. (2008). Secreted APP regulates the function of full-length APP in neurite outgrowth through interaction with integrin beta1. Neural Development, 3, 15.
10.1186/1749-8104-3-15
Younkin, S. G. (1995). Evidence that A beta 42 is the real culprit in Alzheimer’s disease. Annals of Neurology, 37(3), 287–288.
10.1002/ana.410370303
Yu, Y. J., & Watts, R. J. (2013). Developing therapeutic antibodies for neurodegenerative disease. Neurotherapeutics, 10(3), 459–472.
10.1007/s13311-013-0187-4
Yuan, S., Zhou, G., & Xu, G. (2024). Translation machinery: The basis of translational control. Journal of Genetics and Genomics, 51(4), 367–378.
10.1016/j.jgg.2023.07.009
Yusakul, G., Sakamoto, S., Pongkitwitoon, B., Tanaka, H., & Morimoto, S. (2016). Effect of linker length between variable domains of single chain variable fragment antibody against daidzin on its reactivity. Bioscience, Biotechnology and Biochemistry, 80(7), 1306–1312.
10.1080/09168451.2016.1156482
Zameer, A., Kasturirangan, S., Emadi, S., Nimmagadda, S. V., & Sierks, M. R. (2008). Anti-oligomeric Abeta single-chain variable domain antibody blocks Abeta-induced toxicity against human neuroblastoma cells. Journal of Molecular Biology, 384(4), 917–928.
10.1016/j.jmb.2008.09.068
Zampagni, M., Cascella, R., Casamenti, F., Grossi, C., Evangelisti, E., Wright, D., Becatti, M., Liguri, G., Mannini, B., Campioni, S., Chiti, F., & Cecchi, C. (2011). A comparison of the biochemical modifications caused by toxic and non-toxic protein oligomers in cells. Journal of Cellular and Molecular Medicine, 15(10), 2106–2116.
10.1111/j.1582-4934.2010.01239.x
Zandomeneghi, G., Krebs, M. R. H., McCammon, M. G., & Fändrich, M. (2004). FTIR reveals structural differences between native beta-sheet proteins and amyloid fibrils. Protein Science, 13(12), 3314–3321.
10.1110/ps.041024904
Zetterberg, H., & Bendlin, B. B. (2021). Biomarkers for Alzheimer’s disease-preparing for a new era of disease-modifying therapies. Molecular Psychiatry, 26(1), 296–308.
10.1038/s41380-020-0721-9
Zetterberg, H., Alawode, D. O. T., Keshavan, A., O’Connor, A, Weston, P. S. J., Paterson, R. W., Heslegrave, A., Fox, N. C. Fox, Lunn, M. P., & Schott, J. M. (2020). Blood Tests for Alzheimer Disease. Practical Neurology. practicalneurology.com
Zha, J., Liu, X.-M., Zhu, J., Liu, S.-Y., Lu, S., Xu, P.-X., Yu, X.-L., & Liu, R.-T. (2016). A scFv antibody targeting common oligomeric epitope has potential for treating several amyloidoses. Scientific Reports, 6, 36631.
10.1038/srep36631
Zhao, Y., & Zhao, B. (2013). Oxidative stress and the pathogenesis of Alzheimer’s disease. Oxidative Medicine and Cellular Longevity, 2013, 316523.
10.1155/2013/316523
Zheng, F., Pang, Y., Li, L., Pang, Y., Zhang, J., Wang, X., & Raes, G. (2022). Applications of nanobodies in brain diseases. Frontiers in Immunology, 13, 978513.
10.3389/fimm u.2022.978513
Zhu, X., Perry, G., Smith, M. A., & Wang, X. (2013). Abnormal mitochondrial dynamics in the pathogenesis of Alzheimer’s disease. Journal of Alzheimer’s Disease: JAD, 33 Suppl 1, S253-262.
10.3233/JAD-2012-129005